<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103970</article-id><article-id pub-id-type="doi">10.7554/eLife.103970</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.103970.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>Cancer–immune coevolution dictated by antigenic mutation accumulation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Long</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6937-2481</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Morison</surname><given-names>Christo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9350-7833</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Huang</surname><given-names>Weini</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9016-2665</contrib-id><email>weini.huang@qmul.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0064kty71</institution-id><institution>Group of Theoretical Biology, Innovation Center for Evolutionary Synthetic Biology School of Life Sciences, Sun Yat-sen University</institution></institution-wrap><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/026zzn846</institution-id><institution>School of Mathematical Sciences, Queen Mary University of London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shou</surname><given-names>Wenying</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>University College London</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Diamond</surname><given-names>Betty</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dnene97</institution-id><institution>The Feinstein Institute for Medical Research</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>10</day><month>10</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP103970</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-11-18"><day>18</day><month>11</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-09-24"><day>24</day><month>09</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.09.10.612074"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-04-16"><day>16</day><month>04</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103970.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-08-26"><day>26</day><month>08</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.103970.2"/></event></pub-history><permissions><copyright-statement>© 2025, Wang et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-103970-v1.pdf"/><abstract><p>The immune system is one of the first lines of defence against cancer. When effector cells attempt to suppress tumour, cancer cells can evolve methods of escape or inhibition. Knowledge of this coevolutionary system can help to understand tumour–immune dynamics both during tumourigenesis and during immunotherapy treatments. Here, we present an individual-based model of mutation accumulation, where random mutations in cancer cells trigger specialised immune responses. Unlike previous research, we explicitly model interactions between cancer and effector cells and incorporate stochastic effects, which are important for the expansion and extinction of small populations. We find that the parameters governing interactions between the cancer and effector cells induce different outcomes of tumour progress, such as suppression and evasion. While it is hard to measure the cancer–immune dynamics directly, genetic information of the cancer may indicate the presence of such interactions. Our model demonstrates signatures of selection in sequencing-derived summary statistics, such as the single-cell mutational burden distribution. Thus, bulk and single-cell sequencing may provide information about the coevolutionary dynamics.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>The human body is made up of around 36 trillion cells and 200 different types of cells, each with a specialised role. For example, immune cells are crucial for fighting infections. They also act as the body’s first line of defence against internal threats, such as cancer.</p><p>Cells have intricate systems to control how often and how much they divide, ensuring a fresh supply of cells. When some of these signals are faulty or missing, cells can start to grow and multiply uncontrollably. This unchecked growth can form tumours.</p><p>Some immune cells can recognise cancer cells by certain proteins on their surface and mark them for destruction. This process is thought to eliminate many potential tumours before they become dangerous. This way, early cancer can be held in check for years.</p><p>However, cancer cells can evolve genetic changes that help them evade the immune system. In response, immune cells adapt to find new ways to identify these mutations. This creates an evolutionary arms race, with each side developing new strategies to outsmart the other. Eventually, cancer cells may acquire enough changes to grow unchecked, outpacing the immune system.</p><p>So far, it has been unclear whether the interactions between cancer and immune cells leave detectable genetic traces in the DNA of cells. By analysing the DNA of advanced cancers, researchers may be able to reconstruct how tumours interacted with the immune system in the past. These insights could reveal patterns that help predict a tumour’s future behaviour and highlight new treatment opportunities.</p><p>Wang, Morison and Huang built a computer model to study how cancer and the immune system influence each other over time. By examining mutation patterns in tumours, they were able to trace how strongly the immune system shaped cancer growth.</p><p>The results showed that when cancer cells develop certain mutations that make them more visible to the immune system, the immune system launches strong bursts of activity to eliminate them. In this way, the immune system can shape which mutations persist in a tumour. For example, cancer cells with many mutations are more likely to be detected and destroyed. Over time, these strongly targeted cancer cells – and the immune cells that attack them – tend to disappear from the population. However, in some cancers, this effect is much weaker, and the immune system has less influence over the tumour’s genetic changes.</p><p>A key challenge is understanding how cancer mutations arise in the first place. To make progress, researchers will need to combine large-scale population data with detailed single-cell data. This knowledge will be especially important for advancing immunotherapies and other precision cancer treatments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cancer–immune interaction</kwd><kwd>effector cells</kwd><kwd>mutation accumulation</kwd><kwd>stochastic modelling</kwd><kwd>site frequency spectrum</kwd><kwd>single-cell mutation burden distribution</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.3030/955708</award-id><principal-award-recipient><name><surname>Morison</surname><given-names>Christo</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic information in cancer cells reveals the strength of cancer–immune interactions in an individual-based stochastic model, which captures explicit interactions between cancer and effector cells.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The immune system does not only protect our body from infectious diseases caused by various pathogens, but also gives the first response against threats emerging within the body, such as cancer. Immune cells try to identify and eliminate tumour cells, which may express antigens not found on normal cells. Meanwhile, tumour cells attempt to hide or evade from immune surveillance (<xref ref-type="bibr" rid="bib28">Hanahan, 2022</xref>). From an ecological perspective, this antagonistic relationship gives rise to complex dynamics between a tumour and its microenvironment (<xref ref-type="bibr" rid="bib15">Dujon et al., 2021</xref>; <xref ref-type="bibr" rid="bib33">Kareva et al., 2021</xref>). On an evolutionary level, these two cell types, though belonging to the same organism, coevolve, each adapting to genotypic and phenotypic changes in the other population (<xref ref-type="bibr" rid="bib21">George and Levine, 2020</xref>). We are interested in the eco-evolutionary dynamics of genotype-specific interactions between cancer and immune cells arising from a continuous introduction of new antigens in the context of immune surveillance and escape.</p><p>Dunn et al. described the battle between the immune system and emergent tumours in three stages, termed the three Es of cancer immunoediting (<xref ref-type="bibr" rid="bib16">Dunn et al., 2004</xref>). The first, Elimination, formulated by Burnet as the immunosurveillance hypothesis, states that the immune system can win this battle and eliminate small cancers (<xref ref-type="bibr" rid="bib8">Burnet, 1957</xref>; <xref ref-type="bibr" rid="bib9">Burnet, 1967</xref>). According to the ‘bad luck’ hypothesis (<xref ref-type="bibr" rid="bib60">Tomasetti and Vogelstein, 2015</xref>), this is a frequent occurrence: only stochastically does the immune system allow cancers to sneak through (<xref ref-type="bibr" rid="bib21">George and Levine, 2020</xref>). Should the cancer do so, it enters Equilibrium. Indeed, some cancers take years to grow to detectable size (<xref ref-type="bibr" rid="bib16">Dunn et al., 2004</xref>), and there is evidence for small persistent tumours coevolving with the immune system (<xref ref-type="bibr" rid="bib36">Koebel et al., 2007</xref>). Finally, Escape, when the cancer evolves mechanisms of evasion and grows to a size that can be detected (<xref ref-type="bibr" rid="bib41">Lakatos et al., 2024</xref>). Deciphering genetic footprints from this coevolutionary process is of utmost clinical relevance from prognosis to treatment (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>), especially since current measures such as immune infiltration, evidence of immune escape and tumour mutational burden are not foolproof markers of immunotherapeutic success and overall survival (<xref ref-type="bibr" rid="bib69">Zapata et al., 2023</xref>).</p><p>Mutations accumulated during cancer evolution increase intratumour heterogeneity, providing a wide landscape of genotypes to improve the tumour’s persistence (<xref ref-type="bibr" rid="bib3">Alexandrov et al., 2013</xref>). Propensities for mutating more rapidly, increasing growth rate, developing metastases, and acquiring resistance to eventual treatment are possible consequences of this accrual of mutations (<xref ref-type="bibr" rid="bib28">Hanahan, 2022</xref>). However, mutations may also alert the immune system of the presence of tumour cells and initiate a suppressive response. This occurs when a mutation acquired by a cancer cell (called an antigenic mutation) results in the presentation by human leukocyte antigen (HLA) of immunogenic peptides called neoantigens at the cell surface (<xref ref-type="bibr" rid="bib46">McGranahan et al., 2017</xref>). These neoantigens are recognisable by cytotoxic T lymphocytes (CTLs), specialised effector cells of the adaptive immune system, which bind to the presented neoantigen via a T cell receptor at their surface and kill the targeted cancer cell (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>). While antigenic mutations are neutral in the absence of an immune response (<xref ref-type="bibr" rid="bib64">Wilkie and Hahnfeldt, 2013</xref>), their fitness in general depends on the likelihood of neoantigen presentation and recognition by effector cells (<xref ref-type="bibr" rid="bib45">Łuksza et al., 2017</xref>).</p><p>Antigenic mutations so targeted by the immune system are thus under negative selective pressure (<xref ref-type="bibr" rid="bib61">Van den Eynden et al., 2019</xref>). The killing of cancer cells carrying antigenic mutations releases further neoantigens, leading to a positive feedback loop of generating immunity to cancer (<xref ref-type="bibr" rid="bib11">Chen and Mellman, 2013</xref>). Cancer cells, however, may in turn combat the immune response via several mechanisms. Cancer cells can inhibit effector cells, such as by expression of programmed cell death-ligand 1, which normally presents in healthy cells to stop the attack of immune cells and can exhaust CTLs interacting with cancer cells that carry it (<xref ref-type="bibr" rid="bib62">Vinay et al., 2015</xref>; <xref ref-type="bibr" rid="bib43">Leschiera, 2022</xref>). Some cancer cells may escape the immune response, such as by reducing neoantigen presentation through down-regulating HLA (<xref ref-type="bibr" rid="bib46">McGranahan et al., 2017</xref>) or by immune editing and losing antigenic mutations due to the immune negative selection (<xref ref-type="bibr" rid="bib54">Puleo and Polyak, 2022</xref>). Cancer cells can even develop immune exclusion, physically restricting the immune cells’ access to the tumour (<xref ref-type="bibr" rid="bib28">Hanahan, 2022</xref>). These processes may arise individually or in concert, and they mean the immune system plays a crucial role in shaping a tumour’s evolution (<xref ref-type="bibr" rid="bib28">Hanahan, 2022</xref>; <xref ref-type="bibr" rid="bib41">Lakatos et al., 2024</xref>).</p><p>Immunotherapies leverage the immune system to reverse the evolution of evasion by mitigating or interfering with these processes (<xref ref-type="bibr" rid="bib43">Leschiera, 2022</xref>). Cytokine-based and tumour-infiltrating leukocyte-based immunotherapies help increase the effector cell population size (<xref ref-type="bibr" rid="bib57">Sotolongo-Costa et al., 2003</xref>; <xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>); immune checkpoint blockade therapies restore the effector response to immune-escaped cancer cells (<xref ref-type="bibr" rid="bib11">Chen and Mellman, 2013</xref>; <xref ref-type="bibr" rid="bib69">Zapata et al., 2023</xref>); other immunotherapies simply boost the ability of CTLs to kill tumour cells (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>; <xref ref-type="bibr" rid="bib29">Heirene et al., 2025</xref>). Understanding of the coevolution between cancer and immune cells, along with the cell-to-cell interactions that drive it, may inform when therapies will succeed—and why.</p><p>There has been a long history of studying antagonistic coevolution experimentally and theoretically (<xref ref-type="bibr" rid="bib47">Mode, 1958</xref>; <xref ref-type="bibr" rid="bib53">Paterson et al., 2010</xref>; <xref ref-type="bibr" rid="bib65">Yamamichi and Ellner, 2016</xref>; <xref ref-type="bibr" rid="bib31">Huang et al., 2017</xref>), with extensive literature on mathematical models of tumour–immune interactions (<xref ref-type="bibr" rid="bib18">Eftimie et al., 2011</xref>; <xref ref-type="bibr" rid="bib43">Leschiera, 2022</xref>; <xref ref-type="bibr" rid="bib27">Hamilton et al., 2022</xref>). Deterministic models often describe the antagonistic relationship between cancer and immune cells as obeying Lotka-Volterra dynamics, with the immune system predating on its tumour prey (<xref ref-type="bibr" rid="bib14">d’Onofrio, 2005</xref>; <xref ref-type="bibr" rid="bib7">Bozic et al., 2024</xref>). Stochastic modelling of the tumour–immune system has been explored by e.g. George and Levine, who characterised escape as a random process with sequential mutations (<xref ref-type="bibr" rid="bib20">George and Levine, 2018</xref>; <xref ref-type="bibr" rid="bib21">George and Levine, 2020</xref>) and subsequently framed cancer evolution as an active optimisation process in response to an evolving immune landscape (<xref ref-type="bibr" rid="bib22">George and Levine, 2021</xref>; <xref ref-type="bibr" rid="bib23">George and Levine, 2023</xref>). In concert with patient sequencing data, Lakatos and colleagues proposed and applied a model of random antigenic mutation accumulation in order to describe the negative selection that neoantigens undergo, resulting in neutral-like evolutionary dynamics (<xref ref-type="bibr" rid="bib41">Lakatos et al., 2024</xref>; <xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>). Recently, Chen et al. included negative frequency dependence in a similar model of antigenic mutation accumulation, so that tumours are only immunogenic when a sufficiently large proportion of their cells present neoantigens, predicting that tumours undergoing this frequency-dependent selection have poorer treatment outcomes than their negative selection counterparts (<xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>).</p><p>Coevolution between the immune system and the threats it faces has often been studied in a gene-for-gene framework, which centres on the genetic makeup of multiple populations being tracked (<xref ref-type="bibr" rid="bib59">Thompson and Burdon, 1992</xref>). However, there is a dearth of stochastic models that explore the explicit evolutionary dynamics of both tumour and immune cell populations (<xref ref-type="bibr" rid="bib22">George and Levine, 2021</xref>): the aforementioned models either encapsulate the immune response into a selection parameter <inline-formula><alternatives><mml:math id="inf1"><mml:mi>s</mml:mi></mml:math><tex-math id="inft1">\begin{document}$s$\end{document}</tex-math></alternatives></inline-formula>, implicitly assuming that effector cells react perfectly and instantaneously to a cancerous threat (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>); or, they are deterministic and thus miss out the critical impact of random processes on small population sizes, while omitting direct genetic information with which sequencing data can be compared (<xref ref-type="bibr" rid="bib37">Korobeinikov et al., 2017</xref>).</p><p>We address this gap in the literature by presenting and analysing a novel stochastic coevolutionary model of tumour–immune dynamics. As in Lakatos et al.’s model, antigenic mutations accrue in cancer cells undergoing a branching process and are negatively selected against by the immune system (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>). The adaptive immune system is represented by specialised effector populations that react to emergent neoantigens (<xref ref-type="bibr" rid="bib2">Adam and Bellomo, 2012</xref>), leading to complex dynamics on both tumour and immune fronts. We focus on interactions between effector cells and their targets, incorporating both active and passive recruitment of effector cells, killing of cancer cells, and inhibition of effectors by cancer cells, while including explicit mechanisms of escape. In particular, we inspect how these interactions are central in determining the evolution of the system. Stochastic simulations allow us to characterise the various dynamics and outcomes that emerge, along with informing the impact of immunotherapy.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Modelling specialised effector response and cancer–immune interactions</title><p>Consider a population of cancer cells undergoing a stochastic branching process with per-capita birth rate <inline-formula><alternatives><mml:math id="inf2"><mml:mi>b</mml:mi></mml:math><tex-math id="inft2">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> and per-capita death rate <inline-formula><alternatives><mml:math id="inf3"><mml:mi>d</mml:mi></mml:math><tex-math id="inft3">\begin{document}$d$\end{document}</tex-math></alternatives></inline-formula> (see <xref ref-type="fig" rid="fig1">Figure 1A</xref>). We assume births and deaths happen randomly based on their rates, with exponentially distributed wait times between events, as in the Gillespie algorithm (<xref ref-type="bibr" rid="bib24">Gillespie, 1976</xref>). At each cancer cell division, daughter cells inherit their mother cell’s mutations and acquire a random number of new mutations, drawn from a Poisson distribution with mean <inline-formula><alternatives><mml:math id="inf4"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>λ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft4">\begin{document}$\lambda$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="bibr" rid="bib42">Lederberg, 1989</xref>), as shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>. Similar to Lakatos et al., we focus on the exomic region (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>), where the value of <inline-formula><alternatives><mml:math id="inf5"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>λ</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft5">\begin{document}$\lambda$\end{document}</tex-math></alternatives></inline-formula> ranges between 1 and 10. All mutations are unique, as in the infinite sites approximation, where the exome is considered long enough for two co-occurring point mutations to be negligible (<xref ref-type="bibr" rid="bib35">Kimura, 1969</xref>). We distinguish between two types of mutations: with probability <inline-formula><alternatives><mml:math id="inf6"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft6">\begin{document}$p_{a}$\end{document}</tex-math></alternatives></inline-formula>, a mutation is antigenic and can be recognised by given effector cells, and with probability <inline-formula><alternatives><mml:math id="inf7"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft7">\begin{document}$1 - p_{a}$\end{document}</tex-math></alternatives></inline-formula> it is neutral (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>; <xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>). Here, we write the antigenic mutations of a cancer cell (labelled by <inline-formula><alternatives><mml:math id="inf8"><mml:mi>ℓ</mml:mi></mml:math><tex-math id="inft8">\begin{document}$\ell$\end{document}</tex-math></alternatives></inline-formula>) as <inline-formula><alternatives><mml:math id="inf9"><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft9">\begin{document}$M_{a, \ell}$\end{document}</tex-math></alternatives></inline-formula> and the neutral mutations as <inline-formula><alternatives><mml:math id="inf10"><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft10">\begin{document}$M_{n, \ell}$\end{document}</tex-math></alternatives></inline-formula><italic>,</italic> where <inline-formula><alternatives><mml:math id="inf11"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mo>∪</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><tex-math id="inft11">\begin{document}$M_{\ell}= M_{a, \ell}\cup M_{n, \ell}$\end{document}</tex-math></alternatives></inline-formula> is the set of all mutations carried by a cancer cell. During a division, there is a probability <inline-formula><alternatives><mml:math id="inf12"><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math><tex-math id="inft12">\begin{document}$p_{e}$\end{document}</tex-math></alternatives></inline-formula> that an antigenic mutation escapes the immune system, therefore making the cell possessing it (and all of its descendants <xref ref-type="bibr" rid="bib5">Baar et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>) undetectable to the immune system (see <xref ref-type="fig" rid="fig1">Figure 1B</xref>), rendering their antigenic mutation sets empty. It is important to note that immune escape is not necessarily a permanent state; cells that have undergone escape may subsequently acquire new antigenic mutations in future divisions, thereby regaining susceptibility to immune detection.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cancer–immune stochastic model.</title><p>(<bold>A</bold>) Cancer cells (red) stochastically divide and die with rates <inline-formula><alternatives><mml:math id="inf13"><mml:mi>b</mml:mi></mml:math><tex-math id="inft13">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf14"><mml:mi>d</mml:mi></mml:math><tex-math id="inft14">\begin{document}$d$\end{document}</tex-math></alternatives></inline-formula>, respectively (here <inline-formula><alternatives><mml:math id="inf15"><mml:mi>⌀</mml:mi></mml:math><tex-math id="inft15">\begin{document}$\varnothing$\end{document}</tex-math></alternatives></inline-formula> represents no cell). (<bold>B</bold>) During a division event, daughter cells inherit all of their mother cell's antigenic and neutral mutations, depicted by numbers (where underlined numbers are antigenic). Cells carrying antigenic mutations have a probability <inline-formula><alternatives><mml:math id="inf16"><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math><tex-math id="inft16">\begin{document}$p_{e}$\end{document}</tex-math></alternatives></inline-formula> to escape and become neutral, as shown in the lower daughter cell with mutation 2. Each daughter cell also acquires a random number (drawn from a Poisson distribution with mean <inline-formula><alternatives><mml:math id="inf17"><mml:mi>λ</mml:mi></mml:math><tex-math id="inft17">\begin{document}$\lambda$\end{document}</tex-math></alternatives></inline-formula>) of new mutations, where each mutation is antigenic with probability <inline-formula><alternatives><mml:math id="inf18"><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math><tex-math id="inft18">\begin{document}$p_{a}$\end{document}</tex-math></alternatives></inline-formula> and neutral with probability <inline-formula><alternatives><mml:math id="inf19"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft19">\begin{document}$1 - p_{a}$\end{document}</tex-math></alternatives></inline-formula>. (<bold>C</bold>) For each antigenic mutation <inline-formula><alternatives><mml:math id="inf20"><mml:mi>i</mml:mi></mml:math><tex-math id="inft20">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> present in the system, a corresponding effector cell population <inline-formula><alternatives><mml:math id="inf21"><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft21">\begin{document}$E_{i}$\end{document}</tex-math></alternatives></inline-formula> exists (blue), whose size grows with constant rate <inline-formula><alternatives><mml:math id="inf22"><mml:mi>B</mml:mi></mml:math><tex-math id="inft22">\begin{document}$B$\end{document}</tex-math></alternatives></inline-formula> and shrinks with per-capita death rate <inline-formula><alternatives><mml:math id="inf23"><mml:mi>D</mml:mi></mml:math><tex-math id="inft23">\begin{document}$D$\end{document}</tex-math></alternatives></inline-formula>. (<bold>D</bold>) Antigenic mutations in cancer cells (such as <inline-formula><alternatives><mml:math id="inf24"><mml:mi>i</mml:mi></mml:math><tex-math id="inft24">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf25"><mml:mi>k</mml:mi></mml:math><tex-math id="inft25">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula>) display unique neoantigens at the cell surface, whereas neutral mutations (such as <inline-formula><alternatives><mml:math id="inf26"><mml:mi>j</mml:mi></mml:math><tex-math id="inft26">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula>) do not. The neoantigens can be identified by specialised effector cells, which can only interact with the corresponding cancer cells. (<bold>E</bold>) When a cancer cell carrying the antigenic mutation <inline-formula><alternatives><mml:math id="inf27"><mml:mi>i</mml:mi></mml:math><tex-math id="inft27">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> meets an effector cell of type <inline-formula><alternatives><mml:math id="inf28"><mml:mi>i</mml:mi></mml:math><tex-math id="inft28">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>, three outcomes are possible: active recruitment of another effector cell of type <inline-formula><alternatives><mml:math id="inf29"><mml:mi>i</mml:mi></mml:math><tex-math id="inft29">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> with rate <inline-formula><alternatives><mml:math id="inf30"><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft30">\begin{document}$\alpha_{i}$\end{document}</tex-math></alternatives></inline-formula>, killing of the cancer cell with rate <inline-formula><alternatives><mml:math id="inf31"><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft31">\begin{document}$\beta_{i}$\end{document}</tex-math></alternatives></inline-formula> and inhibition/exhaustion of the effector cell with rate <inline-formula><alternatives><mml:math id="inf32"><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft32">\begin{document}$\gamma_{i}$\end{document}</tex-math></alternatives></inline-formula>. The expressions for the rates are found in <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-fig1-v1.tif"/></fig><p>Neoantigens trigger responses from the adaptive immune system: each antigenic mutation <inline-formula><alternatives><mml:math id="inf33"><mml:mi>i</mml:mi></mml:math><tex-math id="inft33">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> calls a unique, specialised effector population, as in gene-for-gene coevolution (<xref ref-type="bibr" rid="bib59">Thompson and Burdon, 1992</xref>). We will write <inline-formula><alternatives><mml:math id="inf34"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft34">\begin{document}$(E_{i})$\end{document}</tex-math></alternatives></inline-formula> to denote an effector cell of type <inline-formula><alternatives><mml:math id="inf35"><mml:mi>i</mml:mi></mml:math><tex-math id="inft35">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf36"><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft36">\begin{document}$E_{i}$\end{document}</tex-math></alternatives></inline-formula> to represent the corresponding population size (and, in an abuse of notation, occasionally the population itself, when this will not cause too much confusion). Whenever mutation <inline-formula><alternatives><mml:math id="inf37"><mml:mi>i</mml:mi></mml:math><tex-math id="inft37">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> exists within the population, effector cells of type <inline-formula><alternatives><mml:math id="inf38"><mml:mi>i</mml:mi></mml:math><tex-math id="inft38">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> are passively recruited from the body at constant rate <inline-formula><alternatives><mml:math id="inf39"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>B</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft39">\begin{document}$B$\end{document}</tex-math></alternatives></inline-formula> (<inline-formula><alternatives><mml:math id="inf40"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>∅</mml:mi><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mi>B</mml:mi></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft40">\begin{document}$\varnothing \xrightarrow{B}(E_{i})$\end{document}</tex-math></alternatives></inline-formula>, for <inline-formula><alternatives><mml:math id="inf41"><mml:mi>⌀</mml:mi></mml:math><tex-math id="inft41">\begin{document}$\varnothing$\end{document}</tex-math></alternatives></inline-formula> the absence of a cell, with rate <inline-formula><alternatives><mml:math id="inf42"><mml:mi>B</mml:mi></mml:math><tex-math id="inft42">\begin{document}$B$\end{document}</tex-math></alternatives></inline-formula>), and die with per-capita rate <inline-formula><alternatives><mml:math id="inf43"><mml:mi>D</mml:mi></mml:math><tex-math id="inft43">\begin{document}$D$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="bibr" rid="bib38">Kuznetsov et al., 1994</xref>; <xref ref-type="bibr" rid="bib50">Morselli et al., 2024</xref>), as shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</p><p>To each antigenic mutation <inline-formula><alternatives><mml:math id="inf44"><mml:mi>i</mml:mi></mml:math><tex-math id="inft44">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>, we associate two random numbers, each drawn independently from an exponential distribution with mean 1: an antigenicity <inline-formula><alternatives><mml:math id="inf45"><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft45">\begin{document}$A_{i}$\end{document}</tex-math></alternatives></inline-formula>, describing the propensity for an effector cell <inline-formula><alternatives><mml:math id="inf46"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft46">\begin{document}$(E_{i})$\end{document}</tex-math></alternatives></inline-formula> to kill a cancer cell possessing mutation <inline-formula><alternatives><mml:math id="inf47"><mml:mi>i</mml:mi></mml:math><tex-math id="inft47">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>, and an immunogenicity <inline-formula><alternatives><mml:math id="inf48"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft48">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula>, which relates to the rate at which effector cells of type <inline-formula><alternatives><mml:math id="inf49"><mml:mi>i</mml:mi></mml:math><tex-math id="inft49">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> are recruited during the specified tumour–immune interaction (see equation (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) and <xref ref-type="fig" rid="fig1">Figure 1E</xref>). These can be thought to encapsulate the probability of an antigenic mutation leading to the presentation of neoantigens by HLA molecules and subsequent recognition by CTLs (<xref ref-type="bibr" rid="bib45">Łuksza et al., 2017</xref>).</p><p>Correspondingly, when a cancer cell with an antigenic mutation presents a neoantigen at its surface, only effector cells of the corresponding population can interact with it (<xref ref-type="bibr" rid="bib43">Leschiera, 2022</xref>), as shown in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. We will write <inline-formula><alternatives><mml:math id="inf50"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft50">\begin{document}$(C_{i})$\end{document}</tex-math></alternatives></inline-formula> to denote a cancer cell possessing an antigenic mutation <inline-formula><alternatives><mml:math id="inf51"><mml:mi>i</mml:mi></mml:math><tex-math id="inft51">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf52"><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft52">\begin{document}$C_{i}$\end{document}</tex-math></alternatives></inline-formula> for the corresponding population size. Interactions between cancer cells <inline-formula><alternatives><mml:math id="inf53"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft53">\begin{document}$(C_{i})$\end{document}</tex-math></alternatives></inline-formula> and effector cells <inline-formula><alternatives><mml:math id="inf54"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft54">\begin{document}$(E_{i})$\end{document}</tex-math></alternatives></inline-formula> have three possible outcomes: active recruitment of another effector cell <inline-formula><alternatives><mml:math id="inf55"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft55">\begin{document}$(E_{i})$\end{document}</tex-math></alternatives></inline-formula> with rate <inline-formula><alternatives><mml:math id="inf56"><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft56">\begin{document}$\alpha_{i}$\end{document}</tex-math></alternatives></inline-formula>, killing of the cancer cell <inline-formula><alternatives><mml:math id="inf57"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft57">\begin{document}$(C_{i})$\end{document}</tex-math></alternatives></inline-formula> with rate <inline-formula><alternatives><mml:math id="inf58"><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft58">\begin{document}$\beta_{i}$\end{document}</tex-math></alternatives></inline-formula> and inhibition/exhaustion of the effector cell <inline-formula><alternatives><mml:math id="inf59"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft59">\begin{document}$(E_{i})$\end{document}</tex-math></alternatives></inline-formula> with rate <inline-formula><alternatives><mml:math id="inf60"><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft60">\begin{document}$\gamma_{i}$\end{document}</tex-math></alternatives></inline-formula> (see <xref ref-type="fig" rid="fig1">Figure 1E</xref>). The precise description of the system can be described by the following set of microscopic reactions:<disp-formula id="equ1"><label>(1)</label><alternatives><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="center center" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mspace width="thinmathspace"/><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mi>b</mml:mi></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>∪</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mi mathvariant="normal">′</mml:mi></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>∪</mml:mo><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mi mathvariant="normal">′</mml:mi><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mi>d</mml:mi></mml:mpadded></mml:mover><mml:mi mathvariant="normal">∅</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="normal">∅</mml:mi><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mi>B</mml:mi></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mi>D</mml:mi></mml:mpadded></mml:mover><mml:mi mathvariant="normal">∅</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t1">\begin{document}$$\displaystyle \begin{array}{cc}\,\,(C_{M_\ell})\xrightarrow{b}(C_{M_\ell \cup M^\prime}), (C_{M_\ell \cup M^{\prime\prime}})\\ (C_{M_\ell})\xrightarrow{d}\emptyset\\ \emptyset\xrightarrow{B}(E_{i})\\ (E_{i})\xrightarrow{D}\emptyset\\ (C_{i}), (E_{i})\xrightarrow{\alpha_i}(C_{i}), (E_{i}), (E_{i})\\ (C_{i}), (E_{i})\xrightarrow{\beta_i}(E_{i})\\ (C_{i}), (E_{i})\xrightarrow{\gamma_i}(C_{i})\end{array}$$\end{document}</tex-math></alternatives></disp-formula></p><p>where <inline-formula><alternatives><mml:math id="inf61"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>h</mml:mi><mml:mi>α</mml:mi></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math><tex-math id="inft61">\begin{document}$\alpha_{i}= \frac{\alpha_{0}I_{i}}{1 + \alpha_{0}h_{\alpha}C_{i}I_{i}}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf62"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft62">\begin{document}$\beta_{i}= \beta_{0}A_{i}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf63"><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math><tex-math id="inft63">\begin{document}$\gamma_{i}= \gamma_{0}$\end{document}</tex-math></alternatives></inline-formula>, and <inline-formula><alternatives><mml:math id="inf64"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft64">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf65"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft65">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf66"><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft66">\begin{document}$\gamma_{0}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf67"><mml:msub><mml:mi>h</mml:mi><mml:mi>α</mml:mi></mml:msub></mml:math><tex-math id="inft67">\begin{document}$h_{\alpha}$\end{document}</tex-math></alternatives></inline-formula> are constants for the entire tumour. For simplicity, we will call <inline-formula><alternatives><mml:math id="inf68"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft68">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf69"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft69">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf70"><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft70">\begin{document}$\gamma_{0}$\end{document}</tex-math></alternatives></inline-formula> the recruitment, killing and inhibition rates, respectively, even though they are not strictly rates. We have denoted the cell carrying a set of mutations <inline-formula><alternatives><mml:math id="inf71"><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math><tex-math id="inft71">\begin{document}$M_{\ell}$\end{document}</tex-math></alternatives></inline-formula>, which can be partitioned into antigenic mutations <inline-formula><alternatives><mml:math id="inf72"><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft72">\begin{document}$M_{a, \ell}$\end{document}</tex-math></alternatives></inline-formula> and neutral mutations <inline-formula><alternatives><mml:math id="inf73"><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:math><tex-math id="inft73">\begin{document}$M_{n, \ell}$\end{document}</tex-math></alternatives></inline-formula>, by <inline-formula><alternatives><mml:math id="inf74"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft74">\begin{document}$(C_{M_\ell})$\end{document}</tex-math></alternatives></inline-formula>. Upon division, each daughter cell inherits the full set of mutations from the mother cell and independently acquires additional new mutations, denoted by <inline-formula><alternatives><mml:math id="inf75"><mml:msup><mml:mi>M</mml:mi><mml:mo lspace="0em" rspace="0em" class="tml-prime">′</mml:mo></mml:msup></mml:math><tex-math id="inft75">\begin{document}$M^{\prime}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf76"><mml:msup><mml:mi>M</mml:mi><mml:mrow><mml:mo lspace="0em" rspace="0em" class="tml-prime">′</mml:mo><mml:mo lspace="0em" rspace="0em" class="tml-prime">′</mml:mo></mml:mrow></mml:msup></mml:math><tex-math id="inft76">\begin{document}$M^{\prime\prime}$\end{document}</tex-math></alternatives></inline-formula> for the two daughter cells, respectively. The numbers of newly acquired antigenic and neutral mutations for each daughter cell are drawn independently from Poisson distributions with means <inline-formula><alternatives><mml:math id="inf77"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mi>λ</mml:mi></mml:mrow></mml:math><tex-math id="inft77">\begin{document}$p_{a}\lambda$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf78"><mml:mrow><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo><mml:mi>λ</mml:mi></mml:mrow></mml:math><tex-math id="inft78">\begin{document}$(1 - p_{a}) \lambda$\end{document}</tex-math></alternatives></inline-formula>, respectively. With probability <inline-formula><alternatives><mml:math id="inf79"><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft79">\begin{document}$1 - p_{e}$\end{document}</tex-math></alternatives></inline-formula>, the daughter cell retains the antigenic and neutral mutations of the mother cell. With probability <inline-formula><alternatives><mml:math id="inf80"><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math><tex-math id="inft80">\begin{document}$p_{e}$\end{document}</tex-math></alternatives></inline-formula>, the daughter cell undergoes immune escape, and all mutations (including those inherited and newly acquired) are considered neutral, resulting in empty antigenic mutation set. Note that the reactions of active recruitment and inhibition/exhaustion have opposite effects on the effector cell population; here, we assume <inline-formula><alternatives><mml:math id="inf81"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&gt;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math><tex-math id="inft81">\begin{document}$\alpha_{0}\gt \gamma_{0}$\end{document}</tex-math></alternatives></inline-formula>, the opposite of which is rarely considered (<xref ref-type="bibr" rid="bib51">Nani and Freedman, 2000</xref>), as it leads to net decreasing effector population sizes upon interactions with cancer cells. However, active recruitment <inline-formula><alternatives><mml:math id="inf82"><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft82">\begin{document}$\alpha_{i}$\end{document}</tex-math></alternatives></inline-formula> obeys a type-II functional response rather than a type-I (i.e. linear) response as inhibition/exhaustion <inline-formula><alternatives><mml:math id="inf83"><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft83">\begin{document}$\gamma_{i}$\end{document}</tex-math></alternatives></inline-formula>; this is because there is an upper bound to how quickly new effector cells can be recruited (<xref ref-type="bibr" rid="bib30">Holling, 1959</xref>; <xref ref-type="bibr" rid="bib39">Kuznetsov and Knott, 2001</xref>).</p><p>We are interested in genetic information relating to each of the two populations, which we will use to identify and measure the coevolution between effector and cancer cells. For the cancer cells, we define the following summary statistics: the site frequency <inline-formula><alternatives><mml:math id="inf84"><mml:msub><mml:mi>S</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><tex-math id="inft84">\begin{document}$S_{j}$\end{document}</tex-math></alternatives></inline-formula>, denoting the number of antigenic mutations present in <inline-formula><alternatives><mml:math id="inf85"><mml:mi>j</mml:mi></mml:math><tex-math id="inft85">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula> cells, and the single-cell mutational burden <inline-formula><alternatives><mml:math id="inf86"><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math><tex-math id="inft86">\begin{document}$B_{k}$\end{document}</tex-math></alternatives></inline-formula>, the number of cells that possess <inline-formula><alternatives><mml:math id="inf87"><mml:mi>k</mml:mi></mml:math><tex-math id="inft87">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> antigenic mutations. The conglomeration of these (for non-negative integers <inline-formula><alternatives><mml:math id="inf88"><mml:mi>j</mml:mi></mml:math><tex-math id="inft88">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf89"><mml:mi>k</mml:mi></mml:math><tex-math id="inft89">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula>, respectively) forms the site frequency spectrum (SFS) and the single-cell mutational burden distribution (MBD). These satisfy <inline-formula><alternatives><mml:math id="inf90"><mml:mrow><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>C</mml:mi></mml:msubsup><mml:mi>j</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:msubsup><mml:mi>k</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft90">\begin{document}$\sum_{j = 1}^{C}j S_{j}= \sum_{k = 1}^{M_a}k B_{k}$\end{document}</tex-math></alternatives></inline-formula>, where <inline-formula><alternatives><mml:math id="inf91"><mml:mi>C</mml:mi></mml:math><tex-math id="inft91">\begin{document}$C$\end{document}</tex-math></alternatives></inline-formula> denotes the total population of cancer cells and <inline-formula><alternatives><mml:math id="inf92"><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math><tex-math id="inft92">\begin{document}$M_{a}$\end{document}</tex-math></alternatives></inline-formula> denotes the total number of antigenic mutations across all cancer cells (<xref ref-type="bibr" rid="bib49">Morison et al., 2023</xref><italic><bold>).</bold></italic> We will write <inline-formula><alternatives><mml:math id="inf93"><mml:mi>U</mml:mi></mml:math><tex-math id="inft93">\begin{document}$U$\end{document}</tex-math></alternatives></inline-formula> for this quantity (i.e., for either side of the previous equality), the total number of antigenic mutational occurrences.</p><p>For the effector population, we define the average antigenicity <inline-formula><alternatives><mml:math id="inf94"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft94">\begin{document}$\langle A \rangle$\end{document}</tex-math></alternatives></inline-formula> and the average immunogenicity <inline-formula><alternatives><mml:math id="inf95"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft95">\begin{document}$\langle I \rangle$\end{document}</tex-math></alternatives></inline-formula> as follows:<disp-formula id="equ2"><label>(2)</label><alternatives><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mspace width="1em"/><mml:mtext> and </mml:mtext><mml:mspace width="1em"/><mml:mo fence="false" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo fence="false" stretchy="false">⟩</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t2">\begin{document}$$\displaystyle  \langle A \rangle = \frac{\sum_{i = 1}^{M_a}A_{i}E_{i}}{\sum_{i = 1}^{M_a}E_{i}}\quad \text{ and }\quad \langle I \rangle = \frac{\sum_{i = 1}^{M_a}I_{i}E_{i}}{\sum_{i = 1}^{M_a}E_{i}}.$$\end{document}</tex-math></alternatives></disp-formula></p><p>Models that focus only on the cancer cell populations ascribe an antigenicity to the tumour itself (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>); here, by considering both cancer and effector populations, we can also average the antigenicities and immunogenicities over all effector cells. By choosing to average over the effector cells as in <xref ref-type="disp-formula" rid="equ2">Equation 2</xref>, <inline-formula><alternatives><mml:math id="inf96"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft96">\begin{document}$\langle A \rangle$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf97"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft97">\begin{document}$\langle I \rangle$\end{document}</tex-math></alternatives></inline-formula> become measures of the gene-for-gene immune response and its potency in fighting its tumour target, providing an additional angle on the coevolutionary system not present in single-population models.</p></sec><sec id="s2-2"><title>Cyclic dynamics between antigenicity and immunogenicity</title><p>Antagonism between effector cells and their cancer targets results in a range of complex dynamics. For elevated immune efficacy such as high recruitment and killing rates <inline-formula><alternatives><mml:math id="inf98"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft98">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf99"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft99">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula>, emerging tumours are suppressed in early stages. However, when the probability of escape <inline-formula><alternatives><mml:math id="inf100"><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math><tex-math id="inft100">\begin{document}$p_{e}$\end{document}</tex-math></alternatives></inline-formula> is large enough, then neutral-like dynamics ensue, as most cancer cells evade the immune response. While it is expected that negative selection of the immune system on new antigens will selectively prune cancer cells with more antigenic mutations (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>), this process depends on the effector populations themselves, through the interactions formulated in equation (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>). Since here we explicitly model both tumour and immune cell types, we are able to explore their population dynamics in concert.</p><p>Indeed, we can clearly observe a dynamical response between the cancer and effector cells in single evolutionary trajectories. <xref ref-type="fig" rid="fig2">Figure 2</xref> depicts two representative realisations of our stochastic simulations, one for a lower mutation rate (<inline-formula><alternatives><mml:math id="inf101"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft101">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>) and one for a high mutation rate (<inline-formula><alternatives><mml:math id="inf102"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft102">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), the latter of which can be thought of as representing hyper-mutated tumours (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>). The population dynamics of <xref ref-type="fig" rid="fig2">Figure 2A, C</xref> show the effector population undergoing irregular spikes, following classic in-phase cycles with the cancer population as seen in other antagonistic systems (<xref ref-type="bibr" rid="bib1">Abrams, 2000</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Single stochastic realisations for mutation rate <inline-formula><alternatives><mml:math id="inf103"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft103">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<bold>A, B</bold>) and <inline-formula><alternatives><mml:math id="inf104"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft104">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<bold>C, D</bold>).</title><p>(<bold>A, C</bold>) Population dynamics, where red and blue lines depict total cancer and effector cell populations. (<bold>B, D</bold>) Average immunogenicity (yellow line) and antigenicity (orange line) in the effector population for the corresponding realisation. Vertical dashed grey lines in all panels indicate the timing of effector population spikes, which are consistent with the vertical dashed lines in the Muller plots (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>) showing the dynamics of individual effector phenotypes over time for the same realisations. Interaction parameters: recruitment rate <inline-formula><alternatives><mml:math id="inf105"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft105">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and killing rate <inline-formula><alternatives><mml:math id="inf106"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft106">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula> (<bold>A, B</bold>) and <inline-formula><alternatives><mml:math id="inf107"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft107">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf108"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft108">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula> (<bold>C, D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-fig2-v1.tif"/></fig><p>Higher mutation rates lead to the appearance of more mutants, thus potentially more new types of cancer–immune interactions. Based on previous predator–prey studies (<xref ref-type="bibr" rid="bib68">Yoshida et al., 2003</xref>; <xref ref-type="bibr" rid="bib66">Yamamichi, 2020</xref>), we developed a method to quantify the number of cancer–immune cycles at low and high mutation rates. Different from typical predator–prey systems where the two antagonistic species fluctuate between relatively stable ranges of population sizes (<xref ref-type="bibr" rid="bib68">Yoshida et al., 2003</xref>), the abundances of effector and cancer cells in our system often have increasing trends, as seen in <xref ref-type="fig" rid="fig2">Figure 2A, C</xref>. Consequently, the phase portraits of the abundances of cancer effectors show stochastic and irregular behaviour (see <xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref>), rather than having a closed or open oval shape as in predator–prey systems. This makes it hard to quantify whether a cycle is in-phase or out-of-phase using the shape of the phase portraits as in predator–prey systems (<xref ref-type="bibr" rid="bib32">Jones and Ellner, 2007</xref>; <xref ref-type="bibr" rid="bib52">Papkou et al., 2016</xref>), although visually out-of-phase cycles are rare in our simulations. Instead, we develop a method to quantify the number of cancer–immune cycles in our simulations by tracking the directional changes in phase portraits, validated by using a non-evolving stochastic predator–prey system as a control (see <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>). As expected, the number of cycles increases when the mutation rate is higher (see <xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>). The majority are counter-clockwise cycles, where the cancer population increases first, followed by the increase of the effector population (see <xref ref-type="fig" rid="app1fig7">Appendix 1—figure 7</xref>). However, we also observe a small fraction of clockwise cycles, especially when mutation rate is higher. Clockwise cycles have been observed in various predator–prey systems and could arise as a consequence of coevolution (<xref ref-type="bibr" rid="bib13">Cortez and Weitz, 2014</xref>).</p><p>Because of the specialised nature of our model, these cyclic dynamics arise when a single antigenic mutation <inline-formula><alternatives><mml:math id="inf109"><mml:mi>i</mml:mi></mml:math><tex-math id="inft109">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> causes the rapid active recruitment of the corresponding effector cells (<inline-formula><alternatives><mml:math id="inf110"><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft110">\begin{document}$E_{i}$\end{document}</tex-math></alternatives></inline-formula>) to combat the subclone possessing mutation <inline-formula><alternatives><mml:math id="inf111"><mml:mi>i</mml:mi></mml:math><tex-math id="inft111">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> during that time period. Once mutation <inline-formula><alternatives><mml:math id="inf112"><mml:mi>i</mml:mi></mml:math><tex-math id="inft112">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> is eradicated from the cancer cell population, the effector cells (<inline-formula><alternatives><mml:math id="inf113"><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft113">\begin{document}$E_{i}$\end{document}</tex-math></alternatives></inline-formula>) specialised to their neoantigen are removed from the system, as they no longer play a dynamical role and die out exponentially (see <xref ref-type="fig" rid="fig1">Figure 1C</xref>). The expected frequency and amplitude of these effector spikes can be approximated, as described in section Stochastic analysis of Appendix. We validate this by inspecting the coevolution of antigenicity and immunogenicity in the corresponding single realisations. In <xref ref-type="fig" rid="fig2">Figure 2</xref>, we can see that the effector spikes arise due to the emergence of one or several mutations that have a large immunogenicity <inline-formula><alternatives><mml:math id="inf114"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft114">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>) dominating the average immunogenicity in the effector population (<xref ref-type="fig" rid="fig2">Figure 2B, D</xref>). Unexpectedly, in addition to this elevated immunogenicity, <xref ref-type="fig" rid="fig2">Figure 2B, D</xref> as well as <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref> imply that these spikes also arise for mutations with low antigenicity. These fluctuations in <inline-formula><alternatives><mml:math id="inf115"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft115">\begin{document}$\langle I \rangle$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf116"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft116">\begin{document}$\langle A \rangle$\end{document}</tex-math></alternatives></inline-formula> are coupled to the spikes in the population size (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>); had a mutation emerged with a large antigenicity, it would have been quickly eradicated, and so the effector population size would not have grown sufficiently to be identified as a spike. As expected, the higher mutation rate (<inline-formula><alternatives><mml:math id="inf117"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft117">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>) leads to more cycles of spikes not only in the cancer–effector dynamics but also in the coevolution of antigenicity and immunogenicity dynamics.</p></sec><sec id="s2-3"><title>Interactions dictate the outcome of tumour progress</title><p>The outcome of the coevolution between the immune system and a tumour depends strongly on the interaction parameters between effector and cancer cells (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>). <xref ref-type="fig" rid="fig3">Figure 3A, D</xref> illustrates heat maps for the tumour suppression proportion across different values of the active effector recruitment rate <inline-formula><alternatives><mml:math id="inf118"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft118">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> and the cancer killing rate <inline-formula><alternatives><mml:math id="inf119"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft119">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula>. Due to the stochastic nature of the model, the outcome for a given parameter set is probabilistic. As expected, for higher values of <inline-formula><alternatives><mml:math id="inf120"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft120">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf121"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft121">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula>, more effector cells are recruited and more cancer cells are killed, thus the suppression increased. While this pattern holds for different mutation rates (<xref ref-type="fig" rid="fig3">Figure 3</xref>), it is more dominating when mutation rate is high. For a higher mutation rate (<inline-formula><alternatives><mml:math id="inf122"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft122">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), the immune system is more effective since there are more antigenic mutations to target, resulting in a high suppression (see <xref ref-type="fig" rid="fig3">Figure 3D</xref>). For a lower mutation rate (<inline-formula><alternatives><mml:math id="inf123"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft123">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>), however, only a small proportion of tumours are suppressed even with strong immune response (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). This is because only a fraction of the population is antigenic (and thus undergoing immunoselection): observe <xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10A–C versus D–F</xref>. It is also worth noting that in this case most suppressed tumours go extinct at early times (<xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9A</xref>) due to stochasticity.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Outcome heat maps for mutation rate <inline-formula><alternatives><mml:math id="inf124"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft124">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<bold>A–C</bold>) and <inline-formula><alternatives><mml:math id="inf125"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft125">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<bold>D–F</bold>) for tumours interacting with an immune system characterised by cancer cell–effector cell interaction parameters <inline-formula><alternatives><mml:math id="inf126"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft126">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> (active recruitment of effectors) and <inline-formula><alternatives><mml:math id="inf127"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft127">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula> (killing of cancer cells).</title><p>(<bold>A, D</bold>) Proportion of suppressed tumours. (<bold>B, E</bold>) Proportion of extinct tumours. (<bold>C, F</bold>) Proportion of slow-growing tumours: tumours that are suppressed but do not go extinct. Points <inline-formula><alternatives><mml:math id="inf128"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>a</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft128">\begin{document}$a$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf129"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>b</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft129">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> (<inline-formula><alternatives><mml:math id="inf130"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>c</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft130">\begin{document}$c$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf131"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>d</mml:mi></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft131">\begin{document}$d$\end{document}</tex-math></alternatives></inline-formula> for <inline-formula><alternatives><mml:math id="inf132"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>λ</mml:mi><mml:mo>=</mml:mo><mml:mn>10</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft132">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>) label parameter sets of low and high immune effectiveness, respectively. The red dashed line denotes inhibition rate <inline-formula><alternatives><mml:math id="inf133"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft133">\begin{document}$\gamma_{0}$\end{document}</tex-math></alternatives></inline-formula> (here <inline-formula><alternatives><mml:math id="inf134"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft134">\begin{document}$\gamma_{0}= 10^{-3}$\end{document}</tex-math></alternatives></inline-formula>); see the Discussion section for details of point <inline-formula><alternatives><mml:math id="inf135"><mml:mi>e</mml:mi></mml:math><tex-math id="inft135">\begin{document}$e$\end{document}</tex-math></alternatives></inline-formula>. All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-fig3-v1.tif"/></fig><p>When the active effector recruitment rate is smaller than the effector inhibiting rate <inline-formula><alternatives><mml:math id="inf136"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&lt;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math><tex-math id="inft136">\begin{document}$\alpha_{0}\lt \gamma_{0}$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="fig3">Figure 3</xref>, red dashed line), the net outcome for effectors during an interaction is negative. This implies that the resulting suppressed tumours in this parameter region were either defeated by a passively recruited effector population, or by effector types <inline-formula><alternatives><mml:math id="inf137"><mml:mi>i</mml:mi></mml:math><tex-math id="inft137">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> corresponding to antigenic mutations with particularly high immunogenicities <inline-formula><alternatives><mml:math id="inf138"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft138">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula>. This is possible since <inline-formula><alternatives><mml:math id="inf139"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft139">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula> is drawn from an exponential distribution (and thus can be high), meaning that even when <inline-formula><alternatives><mml:math id="inf140"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft140">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> is low, the active recruitment can be greater than the inhibition/exhaustion by chance. This is exactly what we observed in our stochastic simulations. Under high mutation rate (<inline-formula><alternatives><mml:math id="inf141"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft141">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), most tumours are not suppressed under low recruitment and killing rates <inline-formula><alternatives><mml:math id="inf142"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft142">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf143"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft143">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), whereas for high interaction parameters most tumours go extinct (<xref ref-type="fig" rid="fig3">Figure 3E</xref>) rather than maintaining a slow growing pace (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Again, we see a similar pattern under a low mutation rate (<inline-formula><alternatives><mml:math id="inf144"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft144">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>), though more weakly and with more noise.</p><p>Interestingly, for a high mutation rate, there exists an intermediate range of interaction parameters that allows for tumours to neither go extinct nor to grow to capacity (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). One further interpretation of <xref ref-type="fig" rid="fig3">Figure 3D</xref> is the presence of a killing threshold (here, at <inline-formula><alternatives><mml:math id="inf145"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>≈</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo lspace="0em" rspace="0em">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><tex-math id="inft145">\begin{document}$\beta_{0}\approx 10^{-1}$\end{document}</tex-math></alternatives></inline-formula>) above which tumours are suppressed, no matter the active recruitment rate <inline-formula><alternatives><mml:math id="inf146"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft146">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula>. The rest of the domain of <xref ref-type="fig" rid="fig3">Figure 3D</xref> then exhibits a much stronger dependence on the active recruitment rate <inline-formula><alternatives><mml:math id="inf147"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft147">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula>, in line with the results of <xref ref-type="bibr" rid="bib64">Wilkie and Hahnfeldt, 2013</xref>.</p></sec><sec id="s2-4"><title>Genetic markers of selection</title><p>Stochastic mutation accumulation in an exponentially growing population has been widely studied (<xref ref-type="bibr" rid="bib17">Durrett, 2013</xref>; <xref ref-type="bibr" rid="bib6">Bozic et al., 2016</xref>). When the immune system has little impact on the cancer cell population, therefore, it is unsurprising to see consistent increases in the average number of mutations per cancer cell, as in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. The theoretical expectation of neutrally accumulated mutations can be approximated by the average flux of number of new mutations entering the system, <inline-formula><alternatives><mml:math id="inf148"><mml:mrow><mml:mn>2</mml:mn><mml:mi>b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:math><tex-math id="inft148">\begin{document}$2bt$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="bibr" rid="bib55">Samuels, 1971</xref>), as plotted in <xref ref-type="fig" rid="fig4">Figure 4</xref>. (Note that a correction for large times has recently been shown to apply <xref ref-type="bibr" rid="bib58">Stein and Werner, 2025</xref>; <xref ref-type="bibr" rid="bib10">Cheek and Johnston, 2023</xref>, which helps explain why the dashed line over-estimates the simulated data in <xref ref-type="fig" rid="fig4">Figure 4</xref>.) When the effector population is selectively killing, however, possessing more antigenic mutations makes a cancer cell more likely to be killed, so the average number of antigenic mutations per cancer cell does not continuously increase with the population, as shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>. This effect of selection is even more pronounced in the case of a higher mutation rate (<inline-formula><alternatives><mml:math id="inf149"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft149">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), as shown in <xref ref-type="fig" rid="app1fig12">Appendix 1—figure 12</xref>.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Average number of antigenic mutations per cell (solid orange lines) for several representative realisations when <inline-formula><alternatives><mml:math id="inf150"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft150">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>.</title><p>Theoretical prediction for the accumulation of neutral mutations per cell in an exponentially growing population is shown in grey dashed line. (<bold>A</bold>) Low immune effect: recruitment rate <inline-formula><alternatives><mml:math id="inf151"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.002</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft151">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and killing rate <inline-formula><alternatives><mml:math id="inf152"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft152">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>. (<bold>B</bold>) High immune effect: <inline-formula><alternatives><mml:math id="inf153"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft153">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf154"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft154">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>. (Parameter sets chosen as points <inline-formula><alternatives><mml:math id="inf155"><mml:mi>a</mml:mi></mml:math><tex-math id="inft155">\begin{document}$a$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf156"><mml:mi>b</mml:mi></mml:math><tex-math id="inft156">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> from <xref ref-type="fig" rid="fig3">Figure 3A</xref>.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-fig4-v1.tif"/></fig><p>The average number of antigenic mutations per cell is the mean of the MBD: <inline-formula><alternatives><mml:math id="inf157"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>B</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mi>/</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:math><tex-math id="inft157">\begin{document}$\langle B \rangle = U / C$\end{document}</tex-math></alternatives></inline-formula>, which, like the SFS, can be extracted from bulk data. However, single-cell sequencing data can also provide information on the MBD overall, which can be used in combination with bulk information to infer what selection is taking place in the system (<xref ref-type="bibr" rid="bib48">Moeller et al., 2024</xref>). As discussed in section Stochastic analysis of the Appendix, the expected neutral distributions of the SFS and the MBD have been solved (<xref ref-type="bibr" rid="bib26">Gunnarsson et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Morison et al., 2023</xref>), so divergence from these may demonstrate the presence of selection and the strength of cancer–immune interactions. In <xref ref-type="fig" rid="fig5">Figure 5</xref>, the SFS and MBD averaged over 100 realisations are plotted in conjunction with the corresponding theoretical predictions (black dashed line) for the case with no immune response (that is, where all mutations are neutral). The first and third rows (green points) represent neutral mutations, whereas the second and fourth rows (orange points) measure antigenic mutations; for the MBDs, the mean (that is, the value <inline-formula><alternatives><mml:math id="inf158"><mml:mrow><mml:mi>U</mml:mi><mml:mi>/</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:math><tex-math id="inft158">\begin{document}$U / C$\end{document}</tex-math></alternatives></inline-formula>) was plotted in dashed vertical lines for both the simulated data (in green and orange) and the theoretical predictions (in grey), which were calculated with <xref ref-type="disp-formula" rid="equ3 equ4">Equations 3 and 4</xref> of the Appendix.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Genetic markers of selection and cancer–immune interactions for <inline-formula><alternatives><mml:math id="inf159"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft159">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>.</title><p>Panels show the site frequency spectrum (SFS) for neutral (<bold>A, E</bold>) and antigenic mutations (<bold>B, F</bold>), and the single-cell mutational burden distribution (MBD) for neutral (<bold>C, G</bold>) and antigenic mutations (<bold>D, H</bold>). Left-column panels correspond to low immune effectiveness (<inline-formula><alternatives><mml:math id="inf160"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.002</mml:mn></mml:mrow></mml:math><tex-math id="inft160">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf161"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft161">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>, point a in <xref ref-type="fig" rid="fig3">Figure 3</xref>), while right-column panels correspond to high immune effectiveness (recruitment rate <inline-formula><alternatives><mml:math id="inf162"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft162">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula>, killing rate <inline-formula><alternatives><mml:math id="inf163"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft163">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>, point b in <xref ref-type="fig" rid="fig3">Figure 3</xref>). Black dashed lines indicate theoretical predictions under neutral evolution (no immune response). Solid and dashed vertical lines in panels <bold>C</bold>, <bold>D</bold>, <bold>G</bold>, and <bold>H</bold> denote the means of the simulated and theoretical MBDs, respectively. The <inline-formula><alternatives><mml:math id="inf164"><mml:msub><mml:mi>W</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><tex-math id="inft164">\begin{document}$W_{1}$\end{document}</tex-math></alternatives></inline-formula> value represents the Wasserstein distance between the simulated and theoretical MBDs with the number of mutations <inline-formula><alternatives><mml:math id="inf165"><mml:mi>k</mml:mi></mml:math><tex-math id="inft165">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> is rescaled to the interval [0,1], and the number of cells <inline-formula><alternatives><mml:math id="inf166"><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math><tex-math id="inft166">\begin{document}$B_{k}$\end{document}</tex-math></alternatives></inline-formula> is normalised to form a probability density. Results are averaged over 100 realisations; all other parameter values are given in <xref ref-type="table" rid="table1">Table 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-fig5-v1.tif"/></fig><p>We notice that in the case of low immune effectiveness (<xref ref-type="fig" rid="fig3">Figure 3A–D</xref>), there is little deviation from the neutral expectation. When the immune system plays a larger role, however, the distinction is significant, as in <xref ref-type="fig" rid="fig3">Figure 3E–H</xref>. In particular, the cells with more antigenic mutations were more selectively killed by the immune system, so that the tail of the MBD is smaller and the mean is shifted down, as seen most prominently in <xref ref-type="fig" rid="fig3">Figure 3H</xref>. As before, when the mutation rate is higher (<inline-formula><alternatives><mml:math id="inf167"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft167">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), these effects are more striking, as shown in <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>. On the other hand, the SFS shows limited difference from its neutral expectation (<xref ref-type="fig" rid="fig3">Figure 3A, E</xref>), reiterating the importance of integrating single-cell data with bulk sequencing data in identifying immune effects. Under stronger negative selection, we expect a depletion of antigenic mutations from the population and thus lower site frequencies than the theoretical prediction (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>). This is visible as a slight depression of the data compared to the neutral prediction in <xref ref-type="fig" rid="fig3">Figure 3F</xref>, though such an observation is much clearer for a faster immune response, as discussed in section Stochastic analysis.</p></sec><sec id="s2-5"><title>Robustness of our observations</title><p>We have shown systematically how the two key parameters, i.e. the active effector recruitment rates <inline-formula><alternatives><mml:math id="inf168"><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft168">\begin{document}$\alpha_{0}$\end{document}</tex-math></alternatives></inline-formula> and the cancer killing rate <inline-formula><alternatives><mml:math id="inf169"><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:math><tex-math id="inft169">\begin{document}$\beta_{0}$\end{document}</tex-math></alternatives></inline-formula>, impact the early suppression of tumour cells (<xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9</xref>), different outcomes in tumour progression (<xref ref-type="fig" rid="fig3">Figure 3</xref>), as well as the proportion of antigenic cells in tumours (<xref ref-type="fig" rid="fig3">Figure 3</xref>). While there is high stochasticity in the system, we observe consistent patterns in evolutionary outcomes across the parameter space. We then pick up representative parameters from distinct parameter regions (e.g. points <inline-formula><alternatives><mml:math id="inf170"><mml:mi>a</mml:mi></mml:math><tex-math id="inft170">\begin{document}$a$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf171"><mml:mi>b</mml:mi></mml:math><tex-math id="inft171">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> in <xref ref-type="fig" rid="fig3">Figure 3</xref>) to compare the averaged distributions of genetic markers—SFS and single-cell MBDs—between these regions based on many realisations (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Using neutral expectations without immune–cancer interactions as the baseline, we see larger differences (measured by the Wasserstein distance) in single-cell mutation burden distributions (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>, C vs. G, D vs. H) in high immune effectiveness (point <inline-formula><alternatives><mml:math id="inf172"><mml:mi>b</mml:mi></mml:math><tex-math id="inft172">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula>, <xref ref-type="fig" rid="fig3">Figure 3</xref>) compared to lower immune effectiveness (point <inline-formula><alternatives><mml:math id="inf173"><mml:mi>a</mml:mi></mml:math><tex-math id="inft173">\begin{document}$a$\end{document}</tex-math></alternatives></inline-formula>, <xref ref-type="fig" rid="fig3">Figure 3</xref>). We further confirm the robustness of our observations in the whole parameter space using the values of Wasserstein distance. The parameter regions with smaller or larger differences in the single-cell mutation burden distribution compared to the neutral expectation (<xref ref-type="fig" rid="app1fig14">Appendix 1—figure 14</xref>) are consistent with the patterns reflected by the tumour progression (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Coevolution between effector cells and their cancer targets sets the stage for the emergence and subsequent development of a tumour. Based on expansive literature in this field (<xref ref-type="bibr" rid="bib14">d’Onofrio, 2005</xref>; <xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">George and Levine, 2018</xref>), we focus on important perspectives which have not yet been addressed by the previous models: in particular, the stochastic nature of these early-stage small cell population sizes as well as explicit interactions between cancer cells and immune cells. Here, we model cancer–immune coevolution, wherein specialised effector cells respond to the presence of randomly accumulated neoantigens in a growing cancer population. We uncover a variety of cancer–immune population dynamics, from the escape or extinction of the tumour to cycles characteristic of antagonistic interactions. We find that the suppression of the tumour by the immune system depends strongly on the cancer–immune interaction parameters, as well as rates of antigenic mutation accumulation in the cancer population. Using mutational distributions, we identify selection and the strength of cancer–immune interactions in the system, arguing for the importance of integrating population- and single-cell-level data, especially in the context of informing immunotherapeutic practices with model predictions.</p><p>Instead of encapsulating the immune impact into a selection parameter, which assumes the effector population reacts immediately and perfectly to any new antigenic mutation (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>), we model the explicit interactions between cancer and immune cells. Our model unveils effector population dynamics during burst-like responses to growing subclones of the cancer population that possess antigenic mutations with high immunogenicity (see <xref ref-type="fig" rid="fig2">Figure 2</xref>). These immune population spikes serve to eliminate specific mutations from the cancer population. Via this selective killing of cancer cells, a process known as immunoselection (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>), the immune system moulds the genetic landscape of the tumour in ways that are identifiable via sequencing data. For instance, the decrease in average antigenic mutations per cell (see <xref ref-type="fig" rid="fig4">Figure 4</xref>) and the truncation of the high-burden tail of the MBD (see <xref ref-type="fig" rid="fig5">Figure 5</xref>) demonstrate that cells with more mutations face stronger negative selection by immune response and are thus pruned from the population. It should be noted, however, that for certain cancers the neoantigenic landscape has been found to be only weakly impacted by cancer–immune coevolution (<xref ref-type="bibr" rid="bib41">Lakatos et al., 2024</xref>). Central to this modelling challenge is understanding the mutational process itself.</p><p>A fraction of somatic mutations arising in cancer populations gives rise to the presentation of neoantigens (<xref ref-type="bibr" rid="bib44">Linnemann et al., 2015</xref>). This is a random process, wherein high mutational loads do not necessarily correspond to high antigenicities (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>). This implies that careful consideration of the mutational burdens of cells as well as the antigenicities of individual mutations is crucial to understanding the resulting evolutionary dynamics of the system. The total mutational burden of the tumour, however, is not a sufficient predictor of response to treatment unless mutations that have escaped are taken into consideration (<xref ref-type="bibr" rid="bib69">Zapata et al., 2023</xref>). While the SFS and the single-cell MBD can inform and help quantify selection (see <xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>), more work needs to be done to understand the impact of different mechanisms of immune escape on genetic data.</p><p>Informing treatment is one of the principal tenets of mathematical modelling in oncology (<xref ref-type="bibr" rid="bib19">Gatenby and Vincent, 2003</xref> <xref ref-type="bibr" rid="bib7">Bozic et al., 2024</xref>). Some immunotherapies increase the ability of effector cells to kill cancer cells (<xref ref-type="bibr" rid="bib56">Schumacher and Schreiber, 2015</xref>), while others, termed immune checkpoint inhibitors, reactivate immune predation in the case of antigenic mutations having escaped detection (<xref ref-type="bibr" rid="bib69">Zapata et al., 2023</xref>). The neoantigens accumulated after escape thus work against the cell once immunotherapy renders the cell visible to the immune system once more, though immune evasion may still impede immunotherapy (<xref ref-type="bibr" rid="bib20">George and Levine, 2018</xref>). If, however, the antigenicities of the cancer cells are low due to immunoselection, the tumour will be less likely to respond well to immune checkpoint inhibition (<xref ref-type="bibr" rid="bib69">Zapata et al., 2023</xref>).</p><p>Few models have explored the relative advantages of different changes in tumour–immune interactions, which represent the impact of immunotherapies discussed above (<xref ref-type="bibr" rid="bib50">Morselli et al., 2024</xref>). Wilkie and Hahnfeldt, for instance, demonstrated that resistance to immune predation plays a smaller role than effector recruitment (<xref ref-type="bibr" rid="bib64">Wilkie and Hahnfeldt, 2013</xref>). Our results show that these relative advantages are highly dependent on the system itself: in <xref ref-type="fig" rid="fig3">Figure 3D</xref>, moving upwards from point <inline-formula><alternatives><mml:math id="inf174"><mml:mi>c</mml:mi></mml:math><tex-math id="inft174">\begin{document}$c$\end{document}</tex-math></alternatives></inline-formula> (decreasing the resistance to predation) has little impact on outcome, whereas moving to the right (increasing recruitment) changes the outcome drastically. Conversely, at point <inline-formula><alternatives><mml:math id="inf175"><mml:mi>e</mml:mi></mml:math><tex-math id="inft175">\begin{document}$e$\end{document}</tex-math></alternatives></inline-formula>, we notice the opposite effect: a change in predation resistance impacts the outcome but a change in recruitment does not. Importantly, only treatments that transform system parameters can succeed in a robust fashion, since only changing the state will still result in the same equilibria as before (<xref ref-type="bibr" rid="bib19">Gatenby and Vincent, 2003</xref>).</p><p>Limitations exist when trying to model the cancer–immune system. When the (antigenic) mutation rate is low, the fraction of the tumour visible to the immune system is too (see <xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10</xref>). The cancer population dynamics are therefore largely neutral (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>), though our model reveals complex effector dynamics. One can also assume a certain antigenic proportion in the tumour before immune recognition (<xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>), or address the growth-threshold conjecture, which states that the immune system will respond to a large enough tumour growth rate, rather than a certain tumour size (<xref ref-type="bibr" rid="bib20">George and Levine, 2018</xref>; <xref ref-type="bibr" rid="bib25">Grossman and Paul, 1992</xref>). The situation can also be further complicated by explicitly considering the composite state of an effector cell in the process of killing its cancer prey as a new conjugate type in the model, as has recently been done by Yang et al., who demonstrated its possible impact on the resulting dynamics, including on the outcome and its time scale (<xref ref-type="bibr" rid="bib67">Yang et al., 2025</xref>).</p><p>By employing an individual-based model, we can compare expected mutational distributions with corresponding genetic data. The signatures of selection and strength of cancer–immune interactions in the system, along with a mechanistic knowledge of these interactions, may help inform us of a tumour’s evolutionary history, along with its immunotherapeutic potential.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Stochastic simulation</title><p>We implemented our model using a standard Gillespie algorithm (<xref ref-type="bibr" rid="bib24">Gillespie, 1976</xref>). Each cancer cell is represented as an individual entity characterised by its unique spectrum of mutations. Similarly, each type of effector cell is modelled as a distinct entity that interacts specifically with cancer cells carrying the corresponding antigenic mutation. When a cancer cell divides, new antigenic mutations may arise in the daughter cells, potentially leading to the emergence of new effector cell types. Consequently, as the tumour population expands, both the number of cancer cells and the diversity of effector cell types increase.</p><p>In the standard Gillespie algorithm, the number of possible ‘reactions’ scales quadratically with the number of cancer cells due to the specialised interaction (defined in <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>), resulting in computational costs that become prohibitive for simulating large tumour populations. To address this challenge, we developed a dynamic dependency graph that tracks the dependencies between reactions and cell types, enabling efficient reuse of computations from previous steps. This optimisation reduces the computational cost per step to a constant, independent of the number of cancer cells.</p><p>A realisation ends when either the cancer cell population size exceeds a threshold <inline-formula><alternatives><mml:math id="inf176"><mml:mi>K</mml:mi></mml:math><tex-math id="inft176">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula>, which we call <italic>no suppression</italic>; goes <italic>extinct</italic>; or the cancer cell remains below <inline-formula><alternatives><mml:math id="inf177"><mml:mi>K</mml:mi></mml:math><tex-math id="inft177">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula> at time <inline-formula><alternatives><mml:math id="inf178"><mml:msub><mml:mi>T</mml:mi><mml:mtext>end</mml:mtext></mml:msub></mml:math><tex-math id="inft178">\begin{document}$T_{\text{end}}$\end{document}</tex-math></alternatives></inline-formula>, which we call <italic>slow-growing</italic>. We call the latter two outcomes—extinction and slow growth of the tumour cell population—<italic>suppression</italic>. While our system is stochastic, different outcomes may arise among individual realisations under the same parameter set and initial condition. Thus, we measure the proportion of simulations ending in a given outcome under different parameter values.</p><p><xref ref-type="table" rid="table1">Table 1</xref> summarises all notation and parameters governing the model, including baseline values used for all simulations unless otherwise specified.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Notation and baseline parameter values.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Symbol</th><th align="left" valign="bottom">Baseline</th><th align="left" valign="bottom">Description</th></tr></thead><tbody><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf179"><mml:mi>b</mml:mi></mml:math><tex-math id="inft179">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> , <inline-formula><alternatives><mml:math id="inf180"><mml:mi>d</mml:mi></mml:math><tex-math id="inft180">\begin{document}$d$\end{document}</tex-math></alternatives></inline-formula></td><td align="char" char="." valign="bottom">1 , 0.1</td><td align="left" valign="bottom">Birth and death rates of a cancer cell</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf181"><mml:mi>λ</mml:mi></mml:math><tex-math id="inft181">\begin{document}$\lambda$\end{document}</tex-math></alternatives></inline-formula></td><td align="char" char="." valign="bottom">1 , 10</td><td align="left" valign="bottom">Mean number of exomic mutations acquired per division per daughter cell</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf182"><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:math><tex-math id="inft182">\begin{document}$p_{a}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom">0.075</td><td align="left" valign="bottom">Probability of a mutation being antigenic (rather than neutral)</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf183"><mml:msub><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:msub></mml:math><tex-math id="inft183">\begin{document}$p_{e}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom">10<sup>–6</sup></td><td align="left" valign="bottom">Probability of escape of an antigenic cancer cell into neutrality</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf184"><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft184">\begin{document}$C_{i}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Population of cancer cells carrying antigenic mutation <inline-formula><alternatives><mml:math id="inf185"><mml:mi>i</mml:mi></mml:math><tex-math id="inft185">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> , with total cancer cell population size <inline-formula><alternatives><mml:math id="inf186"><mml:mi>C</mml:mi></mml:math><tex-math id="inft186">\begin{document}$C$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf187"><mml:msub><mml:mi>E</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft187">\begin{document}$E_{i}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Population of effector cells of type <inline-formula><alternatives><mml:math id="inf188"><mml:mi>i</mml:mi></mml:math><tex-math id="inft188">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> , with total effector cell population <inline-formula><alternatives><mml:math id="inf189"><mml:mi>E</mml:mi></mml:math><tex-math id="inft189">\begin{document}$E$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf190"><mml:mi>B</mml:mi></mml:math><tex-math id="inft190">\begin{document}$B$\end{document}</tex-math></alternatives></inline-formula> , <inline-formula><alternatives><mml:math id="inf191"><mml:mi>D</mml:mi></mml:math><tex-math id="inft191">\begin{document}$D$\end{document}</tex-math></alternatives></inline-formula></td><td align="char" char="." valign="bottom">0.2 , 0.1</td><td align="left" valign="bottom">Passive recruitment and per-capita death of an effector cell</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf192"><mml:msub><mml:mi>α</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft192">\begin{document}$\alpha_{i}$\end{document}</tex-math></alternatives></inline-formula> , <inline-formula><alternatives><mml:math id="inf193"><mml:msub><mml:mi>β</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft193">\begin{document}$\beta_{i}$\end{document}</tex-math></alternatives></inline-formula> , <inline-formula><alternatives><mml:math id="inf194"><mml:msub><mml:mi>γ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft194">\begin{document}$\gamma_{i}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom">—-, —-, 10<sup>–3</sup></td><td align="left" valign="bottom">Active recruitment, killing and inhibition/exhaustion rates, respectively, for interactions between cancer and effector cells of type <inline-formula><alternatives><mml:math id="inf195"><mml:mi>i</mml:mi></mml:math><tex-math id="inft195">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf196"><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft196">\begin{document}$A_{i}$\end{document}</tex-math></alternatives></inline-formula> , <inline-formula><alternatives><mml:math id="inf197"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft197">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Antigenicity and immunogenicity, respectively, of antigenic mutation <inline-formula><alternatives><mml:math id="inf198"><mml:mi>i</mml:mi></mml:math><tex-math id="inft198">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> (each drawn from <inline-formula><alternatives><mml:math id="inf199"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mtext>Exp</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft199">\begin{document}$\text{Exp}(1)$\end{document}</tex-math></alternatives></inline-formula>), with averages over the effector population <inline-formula><alternatives><mml:math id="inf200"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft200">\begin{document}$\langle A \rangle$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf201"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft201">\begin{document}$\langle I \rangle$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf202"><mml:msub><mml:mi>S</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:math><tex-math id="inft202">\begin{document}$S_{j}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Site frequency: number of antigenic mutations occurring <inline-formula><alternatives><mml:math id="inf203"><mml:mi>j</mml:mi></mml:math><tex-math id="inft203">\begin{document}$j$\end{document}</tex-math></alternatives></inline-formula> times</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf204"><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:math><tex-math id="inft204">\begin{document}$B_{k}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Single-cell mutational burden: number of cancer cells with <inline-formula><alternatives><mml:math id="inf205"><mml:mi>k</mml:mi></mml:math><tex-math id="inft205">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> antigenic mutations</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf206"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mo separator="true">,</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><tex-math id="inft206">\begin{document}$M_{a, \ell}, M_{n, \ell}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Set of antigenic and neutral mutations, respectively, carried by a cancer cell <inline-formula><alternatives><mml:math id="inf207"><mml:mi>ℓ</mml:mi></mml:math><tex-math id="inft207">\begin{document}$\ell$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf208"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo separator="true">,</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>n</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft208">\begin{document}$M_{a}, M_{n}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Total number of all antigenic and neutral mutations: <inline-formula><alternatives><mml:math id="inf209"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>|</mml:mi><mml:msub><mml:mo movablelimits="false">⋃</mml:mo><mml:mi>ℓ</mml:mi></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mi>|</mml:mi></mml:mrow></mml:math><tex-math id="inft209">\begin{document}$M_{a}= |\bigcup_{\ell}M_{a, \ell}|$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf210"><mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>|</mml:mi><mml:msub><mml:mo movablelimits="false">⋃</mml:mo><mml:mi>ℓ</mml:mi></mml:msub><mml:msub><mml:mi>M</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mi>|</mml:mi></mml:mrow></mml:math><tex-math id="inft210">\begin{document}$M_{n}= |\bigcup_{\ell}M_{n, \ell}|$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf211"><mml:mi>U</mml:mi></mml:math><tex-math id="inft211">\begin{document}$U$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Total antigenic mutational occurrences: <inline-formula><alternatives><mml:math id="inf212"><mml:mrow><mml:mi>U</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>C</mml:mi></mml:msubsup><mml:mi>j</mml:mi><mml:msub><mml:mi>S</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:msubsup><mml:mi>k</mml:mi><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft212">\begin{document}$U = \sum_{j = 1}^{C}j S_{j}= \sum_{k = 1}^{M_a}k B_{k}$\end{document}</tex-math></alternatives></inline-formula></td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf213"><mml:mi>K</mml:mi></mml:math><tex-math id="inft213">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom">3 × 10<sup>4</sup></td><td align="left" valign="bottom">Ending cancer population size for stochastic simulations</td></tr><tr><td align="left" valign="bottom"><inline-formula><alternatives><mml:math id="inf214"><mml:msub><mml:mi>T</mml:mi><mml:mtext>end</mml:mtext></mml:msub></mml:math><tex-math id="inft214">\begin{document}$T_{\text{end}}$\end{document}</tex-math></alternatives></inline-formula></td><td align="left" valign="bottom">16</td><td align="left" valign="bottom">Maximum time for a simulation</td></tr></tbody></table></table-wrap></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-103970-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. Modelling code is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/Bio421/CancerImmuneCoevo">https://github.com/Bio421/CancerImmuneCoevo</ext-link> (copy archived at <xref ref-type="bibr" rid="bib63">Wang, 2025</xref>).</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The evolution of predator-prey interactions: theory and evidence</article-title><source>Annual Review of Ecology and Systematics</source><volume>31</volume><fpage>79</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1146/annurev.ecolsys.31.1.79</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>JA</given-names></name><name><surname>Bellomo</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><source>A Survey of Models for Tumor-Immune System Dynamics</source><publisher-name>Springer Science &amp; Business Media</publisher-name></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Bolli</surname><given-names>N</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Burkhardt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Eyfjörd</surname><given-names>JE</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Greaves</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Ilicic</surname><given-names>T</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Valdés-Mas</surname><given-names>R</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>van ’t Veer</surname><given-names>L</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Yates</surname><given-names>LR</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname><given-names>CF</given-names></name><name><surname>Herrero</surname><given-names>MA</given-names></name><name><surname>Cuesta</surname><given-names>JA</given-names></name><name><surname>Acosta</surname><given-names>FJ</given-names></name><name><surname>Fernández-Arias</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The growth threshold conjecture: a theoretical framework for understanding T-cell tolerance</article-title><source>Royal Society Open Science</source><volume>2</volume><elocation-id>150016</elocation-id><pub-id pub-id-type="doi">10.1098/rsos.150016</pub-id><pub-id pub-id-type="pmid">26587263</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baar</surname><given-names>M</given-names></name><name><surname>Coquille</surname><given-names>L</given-names></name><name><surname>Mayer</surname><given-names>H</given-names></name><name><surname>Hölzel</surname><given-names>M</given-names></name><name><surname>Rogava</surname><given-names>M</given-names></name><name><surname>Tüting</surname><given-names>T</given-names></name><name><surname>Bovier</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A stochastic model for immunotherapy of cancer</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>24169</elocation-id><pub-id pub-id-type="doi">10.1038/srep24169</pub-id><pub-id pub-id-type="pmid">27063839</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Gerold</surname><given-names>JM</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Quantifying clonal and subclonal passenger mutations in cancer evolution</article-title><source>PLOS Computational Biology</source><volume>12</volume><elocation-id>e1004731</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004731</pub-id><pub-id pub-id-type="pmid">26828429</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Bozic</surname><given-names>I</given-names></name><name><surname>Sholokova</surname><given-names>A</given-names></name><name><surname>Kaveh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Neoantigen evolution and response to checkpoint inhibitor immunotherapy in colorectal cancer</article-title><source>Research square</source><pub-id pub-id-type="doi">10.21203/rs.3.rs-4922340/v1</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnet</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1957">1957</year><article-title>Cancer---a biological approach</article-title><source>British Medical Journal</source><volume>1</volume><elocation-id>779</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.1.5022.779</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnet</surname><given-names>FM</given-names></name></person-group><year iso-8601-date="1967">1967</year><article-title>Immunological aspects of malignant disease</article-title><source>The Lancet</source><volume>289</volume><fpage>1171</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(67)92837-1</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheek</surname><given-names>D</given-names></name><name><surname>Johnston</surname><given-names>SGG</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Ancestral reproductive bias in branching processes</article-title><source>Journal of Mathematical Biology</source><volume>86</volume><elocation-id>70</elocation-id><pub-id pub-id-type="doi">10.1007/s00285-023-01907-7</pub-id><pub-id pub-id-type="pmid">37027075</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DS</given-names></name><name><surname>Mellman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Oncology meets immunology: the cancer-immunity cycle</article-title><source>Immunity</source><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response</article-title><source>Communications Biology</source><volume>7</volume><elocation-id>770</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-024-06460-7</pub-id><pub-id pub-id-type="pmid">38918569</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez</surname><given-names>MH</given-names></name><name><surname>Weitz</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Coevolution can reverse predator-prey cycles</article-title><source>PNAS</source><volume>111</volume><fpage>7486</fpage><lpage>7491</lpage><pub-id pub-id-type="doi">10.1073/pnas.1317693111</pub-id><pub-id pub-id-type="pmid">24799689</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d’Onofrio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences</article-title><source>Physica D</source><volume>208</volume><fpage>220</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1016/j.physd.2005.06.032</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dujon</surname><given-names>AM</given-names></name><name><surname>Aktipis</surname><given-names>A</given-names></name><name><surname>Alix-Panabières</surname><given-names>C</given-names></name><name><surname>Amend</surname><given-names>SR</given-names></name><name><surname>Boddy</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Capp</surname><given-names>J-P</given-names></name><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Ewald</surname><given-names>P</given-names></name><name><surname>Gatenby</surname><given-names>R</given-names></name><name><surname>Gerlinger</surname><given-names>M</given-names></name><name><surname>Giraudeau</surname><given-names>M</given-names></name><name><surname>Hamede</surname><given-names>RK</given-names></name><name><surname>Hansen</surname><given-names>E</given-names></name><name><surname>Kareva</surname><given-names>I</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name><name><surname>Marusyk</surname><given-names>A</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Metzger</surname><given-names>MJ</given-names></name><name><surname>Nedelcu</surname><given-names>AM</given-names></name><name><surname>Noble</surname><given-names>R</given-names></name><name><surname>Nunney</surname><given-names>L</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Pujol</surname><given-names>P</given-names></name><name><surname>Read</surname><given-names>AF</given-names></name><name><surname>Roche</surname><given-names>B</given-names></name><name><surname>Sebens</surname><given-names>S</given-names></name><name><surname>Solary</surname><given-names>E</given-names></name><name><surname>Staňková</surname><given-names>K</given-names></name><name><surname>Swain Ewald</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>F</given-names></name><name><surname>Ujvari</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identifying key questions in the ecology and evolution of cancer</article-title><source>Evolutionary Applications</source><volume>14</volume><fpage>877</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1111/eva.13190</pub-id><pub-id pub-id-type="pmid">33897809</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>GP</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The three Es of cancer immunoediting</article-title><source>Annual Review of Immunology</source><volume>22</volume><fpage>329</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104803</pub-id><pub-id pub-id-type="pmid">15032581</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durrett</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Population genetics of neutral mutations in exponentially growing cancer cell populations</article-title><source>The Annals of Applied Probability</source><volume>23</volume><fpage>230</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1214/11-aap824</pub-id><pub-id pub-id-type="pmid">23471293</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftimie</surname><given-names>R</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Earn</surname><given-names>DJD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Interactions between the immune system and cancer: a brief review of non-spatial mathematical models</article-title><source>Bulletin of Mathematical Biology</source><volume>73</volume><fpage>2</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s11538-010-9526-3</pub-id><pub-id pub-id-type="pmid">20225137</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Vincent</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Application of quantitative models from population biology and evolutionary game theory to tumor therapeutic strategies</article-title><source>Molecular Cancer Therapeutics</source><volume>2</volume><fpage>919</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">14555711</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JT</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Stochastic modeling of tumor progression and immune evasion</article-title><source>Journal of Theoretical Biology</source><volume>458</volume><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2018.09.012</pub-id><pub-id pub-id-type="pmid">30218648</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JT</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sustained coevolution in a stochastic model of cancer-immune interaction</article-title><source>Cancer Research</source><volume>80</volume><fpage>811</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-2732</pub-id><pub-id pub-id-type="pmid">31862779</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JT</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Implications of tumor-immune coevolution on cancer evasion and optimized immunotherapy</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.12.005</pub-id><pub-id pub-id-type="pmid">33446448</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>JT</given-names></name><name><surname>Levine</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Optimal cancer evasion in a dynamic immune microenvironment generates diverse post-escape tumor antigenicity profiles</article-title><source>eLife</source><volume>12</volume><elocation-id>e82786</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.82786</pub-id><pub-id pub-id-type="pmid">37096883</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>A general method for numerically simulating the stochastic time evolution of coupled chemical reactions</article-title><source>Journal of Computational Physics</source><volume>22</volume><fpage>403</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/0021-9991(76)90041-3</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>Z</given-names></name><name><surname>Paul</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses</article-title><source>PNAS</source><volume>89</volume><fpage>10365</fpage><lpage>10369</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.21.10365</pub-id><pub-id pub-id-type="pmid">1438221</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunnarsson</surname><given-names>EB</given-names></name><name><surname>Leder</surname><given-names>K</given-names></name><name><surname>Foo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Exact site frequency spectra of neutrally evolving tumors: a transition between power laws reveals a signature of cell viability</article-title><source>Theoretical Population Biology</source><volume>142</volume><fpage>67</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.tpb.2021.09.004</pub-id><pub-id pub-id-type="pmid">34560155</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>PT</given-names></name><name><surname>Anholt</surname><given-names>BR</given-names></name><name><surname>Nelson</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Tumour immunotherapy: lessons from predator-prey theory</article-title><source>Nature Reviews. Immunology</source><volume>22</volume><fpage>765</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00719-y</pub-id><pub-id pub-id-type="pmid">35513493</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heirene</surname><given-names>L</given-names></name><name><surname>Byrne</surname><given-names>H</given-names></name><name><surname>Sepp</surname><given-names>A</given-names></name><name><surname>Gaffney</surname><given-names>E</given-names></name><name><surname>Yates</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Understanding antibody–target antigen interactions and the avidity effect using mathematical modelling</article-title><source>Journal of The Royal Society Interface</source><volume>22</volume><elocation-id>20240710</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2024.0710</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holling</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="1959">1959</year><article-title>The components of predation as revealed by a study of small-mammal predation of the european pine sawfly</article-title><source>The Canadian Entomologist</source><volume>91</volume><fpage>293</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.4039/Ent91293-5</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Traulsen</surname><given-names>A</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Hiltunen</surname><given-names>T</given-names></name><name><surname>Becks</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dynamical trade-offs arise from antagonistic coevolution and decrease intraspecific diversity</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>2059</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01957-8</pub-id><pub-id pub-id-type="pmid">29233970</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>LE</given-names></name><name><surname>Ellner</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Effects of rapid prey evolution on predator-prey cycles</article-title><source>Journal of Mathematical Biology</source><volume>55</volume><fpage>541</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1007/s00285-007-0094-6</pub-id><pub-id pub-id-type="pmid">17483952</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kareva</surname><given-names>I</given-names></name><name><surname>Luddy</surname><given-names>KA</given-names></name><name><surname>O’Farrelly</surname><given-names>C</given-names></name><name><surname>Gatenby</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Predator-Prey in tumor-immune interactions: a wrong model or just an incomplete one?</article-title><source>Frontiers in Immunology</source><volume>12</volume><elocation-id>668221</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.668221</pub-id><pub-id pub-id-type="pmid">34531851</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharlamov</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>On the generation numbers of particles in a branching process with overlapping generations</article-title><source>Theory of Probability &amp; Its Applications</source><volume>14</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1137/1114005</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1969">1969</year><article-title>The number of heterozygous nucleotide sites maintained in a finite population due to steady flux of mutations</article-title><source>Genetics</source><volume>61</volume><fpage>893</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1093/genetics/61.4.893</pub-id><pub-id pub-id-type="pmid">5364968</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koebel</surname><given-names>CM</given-names></name><name><surname>Vermi</surname><given-names>W</given-names></name><name><surname>Swann</surname><given-names>JB</given-names></name><name><surname>Zerafa</surname><given-names>N</given-names></name><name><surname>Rodig</surname><given-names>SJ</given-names></name><name><surname>Old</surname><given-names>LJ</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Adaptive immunity maintains occult cancer in an equilibrium state</article-title><source>Nature</source><volume>450</volume><fpage>903</fpage><lpage>907</lpage><pub-id pub-id-type="doi">10.1038/nature06309</pub-id><pub-id pub-id-type="pmid">18026089</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korobeinikov</surname><given-names>A</given-names></name><name><surname>Starkov</surname><given-names>KE</given-names></name><name><surname>Valle</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Modeling cancer evolution: evolutionary escape under immune system control</article-title><source>Journal of Physics</source><volume>811</volume><elocation-id>012004</elocation-id><pub-id pub-id-type="doi">10.1088/1742-6596/811/1/012004</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname><given-names>VA</given-names></name><name><surname>Makalkin</surname><given-names>IA</given-names></name><name><surname>Taylor</surname><given-names>MA</given-names></name><name><surname>Perelson</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis</article-title><source>Bulletin of Mathematical Biology</source><volume>56</volume><fpage>295</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1007/BF02460644</pub-id><pub-id pub-id-type="pmid">8186756</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname><given-names>VA</given-names></name><name><surname>Knott</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Modeling tumor regrowth and immunotherapy</article-title><source>Mathematical and Computer Modelling</source><volume>33</volume><fpage>1275</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1016/S0895-7177(00)00314-9</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakatos</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Schenck</surname><given-names>RO</given-names></name><name><surname>Cross</surname><given-names>WCH</given-names></name><name><surname>Househam</surname><given-names>J</given-names></name><name><surname>Zapata</surname><given-names>L</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Gatenbee</surname><given-names>C</given-names></name><name><surname>Robertson-Tessi</surname><given-names>M</given-names></name><name><surname>Barnes</surname><given-names>CP</given-names></name><name><surname>Anderson</surname><given-names>ARA</given-names></name><name><surname>Sottoriva</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Evolutionary dynamics of neoantigens in growing tumors</article-title><source>Nature Genetics</source><volume>52</volume><fpage>1057</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0687-1</pub-id><pub-id pub-id-type="pmid">32929288</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lakatos</surname><given-names>E</given-names></name><name><surname>Gunasri</surname><given-names>V</given-names></name><name><surname>Zapata</surname><given-names>L</given-names></name><name><surname>Househam</surname><given-names>J</given-names></name><name><surname>Heide</surname><given-names>T</given-names></name><name><surname>Trahearn</surname><given-names>N</given-names></name><name><surname>Swinyard</surname><given-names>O</given-names></name><name><surname>Cisneros</surname><given-names>L</given-names></name><name><surname>Lynn</surname><given-names>C</given-names></name><name><surname>Mossner</surname><given-names>M</given-names></name><name><surname>Kimberley</surname><given-names>C</given-names></name><name><surname>Spiteri</surname><given-names>I</given-names></name><name><surname>Cresswell</surname><given-names>GD</given-names></name><name><surname>Llibre-Palomar</surname><given-names>G</given-names></name><name><surname>Mitchison</surname><given-names>M</given-names></name><name><surname>Maley</surname><given-names>CC</given-names></name><name><surname>Jansen</surname><given-names>M</given-names></name><name><surname>Rodriguez-Justo</surname><given-names>M</given-names></name><name><surname>Bridgewater</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>AM</given-names></name><name><surname>Sottoriva</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Epigenome and early selection determine the tumour-immune evolutionary trajectory of colorectal cancer</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2024.02.12.579956</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lederberg</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Replica plating and indirect selection of bacterial mutants: isolation of preadaptive mutants in bacteria by sib selection</article-title><source>Genetics</source><volume>121</volume><fpage>395</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1093/genetics/121.3.395</pub-id><pub-id pub-id-type="pmid">2653959</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="thesis"><person-group person-group-type="author"><name><surname>Leschiera</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mathematical models of tumour-immune interactions: discrete and continuum approaches</article-title><publisher-name>HAL Openscience</publisher-name></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linnemann</surname><given-names>C</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>Bies</surname><given-names>L</given-names></name><name><surname>Verdegaal</surname><given-names>EME</given-names></name><name><surname>Schotte</surname><given-names>R</given-names></name><name><surname>Calis</surname><given-names>JJA</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Velds</surname><given-names>A</given-names></name><name><surname>Hilkmann</surname><given-names>H</given-names></name><name><surname>Atmioui</surname><given-names>DE</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Haanen</surname><given-names>JBAG</given-names></name><name><surname>Spits</surname><given-names>H</given-names></name><name><surname>van der Burg</surname><given-names>SH</given-names></name><name><surname>Schumacher</surname><given-names>TNM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma</article-title><source>Nature Medicine</source><volume>21</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nm.3773</pub-id><pub-id pub-id-type="pmid">25531942</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łuksza</surname><given-names>M</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Makarov</surname><given-names>V</given-names></name><name><surname>Balachandran</surname><given-names>VP</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Solovyov</surname><given-names>A</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Greenbaum</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</article-title><source>Nature</source><volume>551</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/nature24473</pub-id><pub-id pub-id-type="pmid">29132144</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Rosenthal</surname><given-names>R</given-names></name><name><surname>Hiley</surname><given-names>CT</given-names></name><name><surname>Rowan</surname><given-names>AJ</given-names></name><name><surname>Watkins</surname><given-names>TBK</given-names></name><name><surname>Wilson</surname><given-names>GA</given-names></name><name><surname>Birkbak</surname><given-names>NJ</given-names></name><name><surname>Veeriah</surname><given-names>S</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Herrero</surname><given-names>J</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name><collab>TRACERx Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Allele-Specific HLA loss and immune escape in lung cancer evolution</article-title><source>Cell</source><volume>171</volume><fpage>1259</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.10.001</pub-id><pub-id pub-id-type="pmid">29107330</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mode</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="1958">1958</year><article-title>A mathematical model for the co-evolution of obligate parasites and their hosts</article-title><source>Evolution</source><volume>12</volume><elocation-id>158</elocation-id><pub-id pub-id-type="doi">10.2307/2406026</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moeller</surname><given-names>ME</given-names></name><name><surname>Mon Père</surname><given-names>NV</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Measures of genetic diversification in somatic tissues at bulk and single-cell resolution</article-title><source>eLife</source><volume>12</volume><elocation-id>RP89780</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.89780</pub-id><pub-id pub-id-type="pmid">38265286</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Morison</surname><given-names>C</given-names></name><name><surname>Stark</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Single-cell mutational burden distributions in birth-death processes</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2309.06355">https://arxiv.org/abs/2309.06355</ext-link></element-citation></ref><ref id="bib50"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Morselli</surname><given-names>D</given-names></name><name><surname>Delitala</surname><given-names>ME</given-names></name><name><surname>Jenner</surname><given-names>AL</given-names></name><name><surname>Frascoli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>A hybrid discrete-continuum modelling approach for the interactions of the immune system with oncolytic viral infections</article-title><source>arXiv</source><ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2404.06459">https://arxiv.org/abs/2404.06459</ext-link></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nani</surname><given-names>F</given-names></name><name><surname>Freedman</surname><given-names>HI</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A mathematical model of cancer treatment by immunotherapy</article-title><source>Mathematical Biosciences</source><volume>163</volume><fpage>159</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/s0025-5564(99)00058-9</pub-id><pub-id pub-id-type="pmid">10701303</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papkou</surname><given-names>A</given-names></name><name><surname>Gokhale</surname><given-names>CS</given-names></name><name><surname>Traulsen</surname><given-names>A</given-names></name><name><surname>Schulenburg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Host-parasite coevolution: why changing population size matters</article-title><source>Zoology</source><volume>119</volume><fpage>330</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.zool.2016.02.001</pub-id><pub-id pub-id-type="pmid">27161157</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paterson</surname><given-names>S</given-names></name><name><surname>Vogwill</surname><given-names>T</given-names></name><name><surname>Buckling</surname><given-names>A</given-names></name><name><surname>Benmayor</surname><given-names>R</given-names></name><name><surname>Spiers</surname><given-names>AJ</given-names></name><name><surname>Thomson</surname><given-names>NR</given-names></name><name><surname>Quail</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>F</given-names></name><name><surname>Walker</surname><given-names>D</given-names></name><name><surname>Libberton</surname><given-names>B</given-names></name><name><surname>Fenton</surname><given-names>A</given-names></name><name><surname>Hall</surname><given-names>N</given-names></name><name><surname>Brockhurst</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Antagonistic coevolution accelerates molecular evolution</article-title><source>Nature</source><volume>464</volume><fpage>275</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nature08798</pub-id><pub-id pub-id-type="pmid">20182425</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puleo</surname><given-names>J</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>A Darwinian perspective on tumor immune evasion</article-title><source>Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</source><volume>1877</volume><elocation-id>188671</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188671</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="1971">1971</year><article-title>Distribution of the branching-process population among generations</article-title><source>Journal of Applied Probability</source><volume>8</volume><fpage>655</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.2307/3212230</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sotolongo-Costa</surname><given-names>O</given-names></name><name><surname>Morales Molina</surname><given-names>L</given-names></name><name><surname>Rodríguez Perez</surname><given-names>D</given-names></name><name><surname>Antoranz</surname><given-names>JC</given-names></name><name><surname>Chacón Reyes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Behavior of tumors under nonstationary therapy</article-title><source>Physica D</source><volume>178</volume><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/S0167-2789(03)00005-8</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>A</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>On the patterns of genetic intra-tumor heterogeneity before and after treatment</article-title><source>Genetics</source><volume>230</volume><elocation-id>iyaf101</elocation-id><pub-id pub-id-type="doi">10.1093/genetics/iyaf101</pub-id><pub-id pub-id-type="pmid">40439127</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>JN</given-names></name><name><surname>Burdon</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Gene-for-gene coevolution between plants and parasites</article-title><source>Nature</source><volume>360</volume><fpage>121</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/360121a0</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasetti</surname><given-names>C</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions</article-title><source>Science</source><volume>347</volume><fpage>78</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1126/science.1260825</pub-id><pub-id pub-id-type="pmid">25554788</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Eynden</surname><given-names>J</given-names></name><name><surname>Jiménez-Sánchez</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lack of detectable neoantigen depletion signals in the untreated cancer genome</article-title><source>Nature Genetics</source><volume>51</volume><fpage>1741</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0532-6</pub-id><pub-id pub-id-type="pmid">31768072</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinay</surname><given-names>DS</given-names></name><name><surname>Ryan</surname><given-names>EP</given-names></name><name><surname>Pawelec</surname><given-names>G</given-names></name><name><surname>Talib</surname><given-names>WH</given-names></name><name><surname>Stagg</surname><given-names>J</given-names></name><name><surname>Elkord</surname><given-names>E</given-names></name><name><surname>Lichtor</surname><given-names>T</given-names></name><name><surname>Decker</surname><given-names>WK</given-names></name><name><surname>Whelan</surname><given-names>RL</given-names></name><name><surname>Kumara</surname><given-names>H</given-names></name><name><surname>Signori</surname><given-names>E</given-names></name><name><surname>Honoki</surname><given-names>K</given-names></name><name><surname>Georgakilas</surname><given-names>AG</given-names></name><name><surname>Amin</surname><given-names>A</given-names></name><name><surname>Helferich</surname><given-names>WG</given-names></name><name><surname>Boosani</surname><given-names>CS</given-names></name><name><surname>Guha</surname><given-names>G</given-names></name><name><surname>Ciriolo</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Mohammed</surname><given-names>SI</given-names></name><name><surname>Azmi</surname><given-names>AS</given-names></name><name><surname>Keith</surname><given-names>WN</given-names></name><name><surname>Bilsland</surname><given-names>A</given-names></name><name><surname>Bhakta</surname><given-names>D</given-names></name><name><surname>Halicka</surname><given-names>D</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Aquilano</surname><given-names>K</given-names></name><name><surname>Ashraf</surname><given-names>SS</given-names></name><name><surname>Nowsheen</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Choi</surname><given-names>BK</given-names></name><name><surname>Kwon</surname><given-names>BS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Immune evasion in cancer: Mechanistic basis and therapeutic strategies</article-title><source>Seminars in Cancer Biology</source><volume>35 Suppl</volume><fpage>S185</fpage><lpage>S198</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2015.03.004</pub-id><pub-id pub-id-type="pmid">25818339</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>CancerImmuneCoevo</data-title><version designator="swh:1:rev:33f21ce86ec6b7d777073f1ff76d7f7da87fd49d">swh:1:rev:33f21ce86ec6b7d777073f1ff76d7f7da87fd49d</version><publisher-name>Software Heritage</publisher-name><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:bf02960f106db804130217c1d6b22183ec9a9cd9;origin=https://github.com/Bio421/CancerImmuneCoevo;visit=swh:1:snp:a2e42ce99ba777de47460afc80a7746f099429fc;anchor=swh:1:rev:33f21ce86ec6b7d777073f1ff76d7f7da87fd49d">https://archive.softwareheritage.org/swh:1:dir:bf02960f106db804130217c1d6b22183ec9a9cd9;origin=https://github.com/Bio421/CancerImmuneCoevo;visit=swh:1:snp:a2e42ce99ba777de47460afc80a7746f099429fc;anchor=swh:1:rev:33f21ce86ec6b7d777073f1ff76d7f7da87fd49d</ext-link></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>KP</given-names></name><name><surname>Hahnfeldt</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion</article-title><source>Interface Focus</source><volume>3</volume><elocation-id>20130010</elocation-id><pub-id pub-id-type="doi">10.1098/rsfs.2013.0010</pub-id><pub-id pub-id-type="pmid">24511375</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamichi</surname><given-names>M</given-names></name><name><surname>Ellner</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Antagonistic coevolution between quantitative and Mendelian traits</article-title><source>Proceedings. Biological Sciences</source><volume>283</volume><elocation-id>20152926</elocation-id><pub-id pub-id-type="doi">10.1098/rspb.2015.2926</pub-id><pub-id pub-id-type="pmid">27009218</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yamamichi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><chapter-title>Effects of rapid evolution on population cycles and extinction in predator--prey systems</chapter-title><person-group person-group-type="editor"><name><surname>Mougi</surname><given-names>A</given-names></name></person-group><source>Diversity of Functional Traits and Interactions: Perspectives on Community Dynamics</source><publisher-name>Springer Singapore</publisher-name><fpage>19</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1007/978-981-15-7953-0_2</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Traulsen</surname><given-names>A</given-names></name><name><surname>Altrock</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Integration of immune cell-target cell conjugate dynamics changes the time scale of immune control of cancer</article-title><source>Bulletin of Mathematical Biology</source><volume>87</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1007/s11538-024-01400-2</pub-id><pub-id pub-id-type="pmid">39751899</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>LE</given-names></name><name><surname>Ellner</surname><given-names>SP</given-names></name><name><surname>Fussmann</surname><given-names>GF</given-names></name><name><surname>Hairston</surname><given-names>NG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Rapid evolution drives ecological dynamics in a predator-prey system</article-title><source>Nature</source><volume>424</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nature01767</pub-id><pub-id pub-id-type="pmid">12867979</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zapata</surname><given-names>L</given-names></name><name><surname>Caravagna</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>MJ</given-names></name><name><surname>Lakatos</surname><given-names>E</given-names></name><name><surname>AbdulJabbar</surname><given-names>K</given-names></name><name><surname>Werner</surname><given-names>B</given-names></name><name><surname>Chowell</surname><given-names>D</given-names></name><name><surname>James</surname><given-names>C</given-names></name><name><surname>Gourmet</surname><given-names>L</given-names></name><name><surname>Milite</surname><given-names>S</given-names></name><name><surname>Acar</surname><given-names>A</given-names></name><name><surname>Riaz</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Graham</surname><given-names>TA</given-names></name><name><surname>Sottoriva</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors</article-title><source>Nature Genetics</source><volume>55</volume><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/s41588-023-01313-1</pub-id><pub-id pub-id-type="pmid">36894710</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><p>This appendix is split into two sections: stochastic analysis and extended figures. We first state theoretical distributions from the literature (section Stochastic analysis). Second, we define the neoantigen burden distribution (NBD) and derive its expected distribution, as well as plot the correlation between the mean of the NBD and the mean of the SFS (section Neoantigen burden distribution). We then discuss early dynamics (section Early stochastic dynamics). Next, we investigate the effector cell population spikes and derive approximations for their expected frequency and amplitudes (section Effector cell population spikes). Finally, we discuss the implications of a faster immune response due to an existing effector pool in the body on the genetic evidence for selection (section Faster immune response). Additional figures of stochastic simulations are found in (sections Composition of effector population and Genetics).</p><sec sec-type="appendix" id="s8"><title>Stochastic analysis</title><sec sec-type="appendix" id="s8-1"><title>Expected mutational distributions</title><p>We begin by stating known expressions for the expected SFS and MBD in the case of neutral evolution, which we used for plots in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>. From <xref ref-type="bibr" rid="bib26">Gunnarsson et al., 2021</xref>, the expected neutral SFS at large population size <inline-formula><alternatives><mml:math id="inf215"><mml:mi>K</mml:mi></mml:math><tex-math id="inft215">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula> with mutations accumulating at rate <italic>µ</italic>, conditional on survival (which we do by filtering out the realisations that do not make it to population <inline-formula><alternatives><mml:math id="inf216"><mml:mi>K</mml:mi></mml:math><tex-math id="inft216">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula>) is given by<disp-formula id="equ3"><label>(3)</label><alternatives><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>S</mml:mi><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mtext>survival</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:mi>μ</mml:mi><mml:mi>K</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">∞</mml:mi></mml:mrow></mml:munderover><mml:mfrac><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mstyle displaystyle="false" scriptlevel="0"><mml:mfrac><mml:mi>d</mml:mi><mml:mi>b</mml:mi></mml:mfrac></mml:mstyle><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t3">\begin{document}$$\displaystyle  \mathbb{E}\left[S_{j}\,|\,\text{survival}\right] \approx \mu K \sum_{i = 0}^{\infty} \frac{\left(\tfrac{d}{b}\right)^{i}}{(i + j)(i + j + 1)}. $$\end{document}</tex-math></alternatives></disp-formula></p><p>We take <inline-formula><alternatives><mml:math id="inf217"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft217">\begin{document}$\mu = \lambda(1 - p_{a})$\end{document}</tex-math></alternatives></inline-formula> for neutral mutations, and <inline-formula><alternatives><mml:math id="inf218"><mml:mrow><mml:mi>μ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>λ</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mi>a</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft218">\begin{document}$\mu = \lambda p_{a}$\end{document}</tex-math></alternatives></inline-formula> for antigenic mutations.</p><p>Under the same assumptions, the expected neutral MBD can be calculated as follows <xref ref-type="bibr" rid="bib49">Morison et al., 2023</xref>:<disp-formula id="equ4"><label>(4)</label><alternatives><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mtext>survival</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>≈</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>ℓ</mml:mi><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>ℓ</mml:mi><mml:mi>μ</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mo>≈</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:munder><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>μ</mml:mi><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:msup><mml:mfrac><mml:msup><mml:mi>K</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>μ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>+</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>ℓ</mml:mi><mml:mi>μ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>ℓ</mml:mi><mml:mi>μ</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t4">\begin{document}$$\displaystyle  \mathbb{E}\left[B_{k}\,|\, \text{survival}\right]\approx \sum_{\ell}D_{\ell}\frac{\mathrm{e}^{-\ell\mu}(\ell\mu)^{k}}{k!}\approx \sum_{\ell}\left(\frac{(b + d)\mu\log K}{b - d}\right)^{\ell}\frac{K^{-\mu(b + d)/ (b - d)}}{\ell!}\frac{\mathrm{e}^{-\ell\mu}(\ell\mu)^{k}}{k!},$$\end{document}</tex-math></alternatives></disp-formula></p><p>where the sum over <inline-formula><alternatives><mml:math id="inf219"><mml:mi>ℓ</mml:mi></mml:math><tex-math id="inft219">\begin{document}$\ell$\end{document}</tex-math></alternatives></inline-formula> spans at most the number of events (births or deaths), though the sum converges faster. We have used a continuous-time approximate version from <xref ref-type="bibr" rid="bib34">Kharlamov, 1969</xref> for the expected division distribution <inline-formula><alternatives><mml:math id="inf220"><mml:msub><mml:mi>D</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math><tex-math id="inft220">\begin{document}$D_{\ell}$\end{document}</tex-math></alternatives></inline-formula> instead of the discrete-time expression from <xref ref-type="bibr" rid="bib49">Morison et al., 2023</xref> for ease of computation, along with the approximation that the population grows to <inline-formula><alternatives><mml:math id="inf221"><mml:mi>K</mml:mi></mml:math><tex-math id="inft221">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula> in <inline-formula><alternatives><mml:math id="inf222"><mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:mo>⁡</mml:mo><mml:mspace width="0.1667em"/></mml:mrow><mml:mi>K</mml:mi><mml:mi>/</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mi>b</mml:mi><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft222">\begin{document}$\log K / (b - d)$\end{document}</tex-math></alternatives></inline-formula> time, which arises by inspection of the deterministic case of exponential growth.</p></sec><sec sec-type="appendix" id="s8-2"><title>Neoantigen burden distribution</title><p>The immune system reacts to the antigenicities of the antigenic mutations possessed by a cancer cell rather than simply its (antigenic) mutational burden. To capture this nuance, we define the neoantigen burden <inline-formula><alternatives><mml:math id="inf223"><mml:msub><mml:mi>N</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math><tex-math id="inft223">\begin{document}$N_{\ell}$\end{document}</tex-math></alternatives></inline-formula> as the number of cells with cumulative antigenicity <inline-formula><alternatives><mml:math id="inf224"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft224">\begin{document}$\sum_{i}A_{i}$\end{document}</tex-math></alternatives></inline-formula> (where the sum spans the antigenic mutations <inline-formula><alternatives><mml:math id="inf225"><mml:mi>i</mml:mi></mml:math><tex-math id="inft225">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> within a cell) in <inline-formula><alternatives><mml:math id="inf226"><mml:mrow><mml:mo form="prefix" stretchy="false">[</mml:mo><mml:mi>ℓ</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft226">\begin{document}$[\ell, \ell + 1)$\end{document}</tex-math></alternatives></inline-formula>. Taken together, the elements <inline-formula><alternatives><mml:math id="inf227"><mml:msub><mml:mi>N</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math><tex-math id="inft227">\begin{document}$N_{\ell}$\end{document}</tex-math></alternatives></inline-formula> form the NBD.</p><p>Following the derivation of the MBD from the division distribution in <xref ref-type="bibr" rid="bib49">Morison et al., 2023</xref>, we write <inline-formula><alternatives><mml:math id="inf228"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>j</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo></mml:mrow><mml:mrow><mml:mtext>Exp</mml:mtext><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft228">\begin{document}$A_{i, j, k}\sim \text{Exp}(1)$\end{document}</tex-math></alternatives></inline-formula> for the antigenicity of the <inline-formula><alternatives><mml:math id="inf229"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>i</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft229">\begin{document}$i{\rm th}$\end{document}</tex-math></alternatives></inline-formula> antigenic mutation of the <inline-formula><alternatives><mml:math id="inf230"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>j</mml:mi><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft230">\begin{document}$j{\rm th}$\end{document}</tex-math></alternatives></inline-formula> cell (for some labelling of cells <inline-formula><alternatives><mml:math id="inf231"><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>≤</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:math><tex-math id="inft231">\begin{document}$1 \leq j \leq B_{k}$\end{document}</tex-math></alternatives></inline-formula>) having a mutational burden of <inline-formula><alternatives><mml:math id="inf232"><mml:mi>k</mml:mi></mml:math><tex-math id="inft232">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf233"><mml:msub><mml:mn mathvariant="double-struck">1</mml:mn><mml:mi>A</mml:mi></mml:msub></mml:math><tex-math id="inft233">\begin{document}$\mathbb {1}_{A}$\end{document}</tex-math></alternatives></inline-formula> for the indicator function that is 1 on the set <inline-formula><alternatives><mml:math id="inf234"><mml:mi>A</mml:mi></mml:math><tex-math id="inft234">\begin{document}$A$\end{document}</tex-math></alternatives></inline-formula> and 0 otherwise. Conditioning on knowledge of the antigenic MBD <inline-formula><alternatives><mml:math id="inf235"><mml:mrow><mml:mo form="prefix" stretchy="false">{</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:msubsup><mml:mo form="postfix" stretchy="false">}</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>M</mml:mi></mml:msubsup></mml:mrow></mml:math><tex-math id="inft235">\begin{document}$\{B_{k}\}_{k = 1}^{M}$\end{document}</tex-math></alternatives></inline-formula>, we find<disp-formula id="equ5"><label>(5)</label><alternatives><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo fence="false" stretchy="false">{</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:munderover><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mn mathvariant="double-struck">1</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mo fence="false" stretchy="false">{</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mo fence="false" stretchy="false">}</mml:mo><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mn mathvariant="double-struck">1</mml:mn></mml:mrow><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>k</mml:mi></mml:munderover><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t5">\begin{document}$$\displaystyle  \mathbb{E}\left[N_{\ell}| \{B_{k}\}_{k}\right]= \mathbb{E}\left[\sum_{k = 1}^{M}\sum_{j = 1}^{B_k}\mathbb {1}_{\left\{\sum_{i = 1}^k A_{i, j, k} \in [\ell, \ell + 1)\right\}}|\{B_{k}\}_{k}\right]= \sum_{k = 1}^{M}B_{k}\mathbb{E}\left[\mathbb{1}_{\left\{\sum_{i = 1}^k A_{i, j, k} \in [\ell, \ell + 1)\right\}}\right].$$\end{document}</tex-math></alternatives></disp-formula></p><p>A sum of <inline-formula><alternatives><mml:math id="inf236"><mml:mi>k</mml:mi></mml:math><tex-math id="inft236">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> exponentially distributed random variables with means <inline-formula><alternatives><mml:math id="inf237"><mml:mi>ν</mml:mi></mml:math><tex-math id="inft237">\begin{document}$\nu$\end{document}</tex-math></alternatives></inline-formula> obeys an Erlang distribution, which has probability density function<disp-formula id="equ6"><label>(6)</label><alternatives><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>;</mml:mo><mml:mi>k</mml:mi><mml:mo>,</mml:mo><mml:mi>ν</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>ν</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>ν</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t6">\begin{document}$$\displaystyle f(t; k, \nu) = \frac{\nu^{k}t^{k - 1}\mathrm{e}^{-\nu t}}{(k - 1)!}.$$\end{document}</tex-math></alternatives></disp-formula></p><p>We take expectations of both sides of <xref ref-type="disp-formula" rid="equ5">Equation 5</xref> (where <inline-formula><alternatives><mml:math id="inf238"><mml:mrow><mml:mi>ν</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft238">\begin{document}$\nu = 1$\end{document}</tex-math></alternatives></inline-formula>) and use the law of total expectation <inline-formula><alternatives><mml:math id="inf239"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix">[</mml:mo><mml:mi>X</mml:mi><mml:mo fence="true" form="postfix">]</mml:mo></mml:mrow><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix">[</mml:mo><mml:mi mathvariant="double-struck">E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix">[</mml:mo><mml:mi>X</mml:mi><mml:mi>|</mml:mi><mml:mi>Y</mml:mi><mml:mo fence="true" form="postfix">]</mml:mo></mml:mrow><mml:mo fence="true" form="postfix">]</mml:mo></mml:mrow></mml:mrow></mml:math><tex-math id="inft239">\begin{document}$\mathbb{E}\left[X\right]= \mathbb{E}\left[\mathbb{E}\left[X | Y\right]\right]$\end{document}</tex-math></alternatives></inline-formula> and <xref ref-type="disp-formula" rid="equ6">Equation 6</xref> to find<disp-formula id="equ7"><label>(7)</label><alternatives><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mfrac><mml:mrow><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msup><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:munderover><mml:mrow><mml:mi mathvariant="double-struck">E</mml:mi></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mfrac><mml:mrow><mml:msup><mml:mi>ℓ</mml:mi><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>!</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mstyle></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t7">\begin{document}$$\displaystyle  \mathbb{E}\left[N_{\ell}\right]= \sum_{k = 1}^{M}\mathbb{E}\left[B_{k}\right]\int_{\ell}^{\ell + 1}\frac{t^{k - 1}\mathrm{e}^{-t}}{(k - 1)!}\, \mathrm{d}t = \mathrm{e}^{-\ell}\sum_{k = 1}^{M}\mathbb{E}\left[B_{k}\right]\sum_{k' = 0}^{k - 1}\frac{\ell^{k'}- \mathrm{e}^{-1}(\ell + 1)^{k'}}{k'!}.$$\end{document}</tex-math></alternatives></disp-formula></p><p>This allows for a flexible definition of the NBD: we have chosen to discretise at integer intervals <inline-formula><alternatives><mml:math id="inf240"><mml:mrow><mml:mo form="prefix" stretchy="false">[</mml:mo><mml:mi>ℓ</mml:mi><mml:mo separator="true">,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft240">\begin{document}$[\ell, \ell + 1)$\end{document}</tex-math></alternatives></inline-formula>, but could have kept it continuous with probability density function <inline-formula><alternatives><mml:math id="inf241"><mml:mrow><mml:msub><mml:mo movablelimits="false">∑</mml:mo><mml:mi>k</mml:mi></mml:msub><mml:mi mathvariant="double-struck">E</mml:mi><mml:mrow><mml:mo fence="true" form="prefix">[</mml:mo><mml:msub><mml:mi>B</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo fence="true" form="postfix">]</mml:mo></mml:mrow><mml:msup><mml:mi>t</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo lspace="0em" rspace="0em">−</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mi>/</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn><mml:mo form="postfix" stretchy="false">)</mml:mo><mml:mo form="postfix" stretchy="false">!</mml:mo></mml:mrow></mml:math><tex-math id="inft241">\begin{document}$\sum_{k}\mathbb{E}\left[B_{k}\right]t^{k - 1}\mathrm{e}^{-t}/ (k - 1)!$\end{document}</tex-math></alternatives></inline-formula>.</p><p><xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2</xref> depicts the average NBD (along with the corresponding construction for the immunogenicity) over 100 realisations, when <inline-formula><alternatives><mml:math id="inf242"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft242">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2A, B</xref>) and when <inline-formula><alternatives><mml:math id="inf243"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft243">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="app1fig2">Appendix 1—figure 2C, D</xref>). Both low and high immune impact parameter sets are plotted, to demonstrate that much like the MBD (see <xref ref-type="fig" rid="fig5">Figure 5</xref> and <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref>), the tail of the distribution is shortened in the case of higher selection. This is because cells with higher antigenicities (likewise for those with higher immunogenicities) face stronger negative selection from the effector population.</p></sec><sec sec-type="appendix" id="s8-3"><title>Early stochastic dynamics</title><p>On average, an effector population of type <inline-formula><alternatives><mml:math id="inf244"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft244">\begin{document}$i = 1$\end{document}</tex-math></alternatives></inline-formula> will have passive capacity <inline-formula><alternatives><mml:math id="inf245"><mml:mrow><mml:mi>B</mml:mi><mml:mi>/</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:math><tex-math id="inft245">\begin{document}$B / D$\end{document}</tex-math></alternatives></inline-formula>: that is, at a population of <inline-formula><alternatives><mml:math id="inf246"><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mi>/</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:math><tex-math id="inft246">\begin{document}$E_{1}= B / D$\end{document}</tex-math></alternatives></inline-formula>, its passive recruitment rate and death rate are equal, and thus ignoring its interactions with its target population <inline-formula><alternatives><mml:math id="inf247"><mml:msub><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><tex-math id="inft247">\begin{document}$C_{1}$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf248"><mml:msub><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><tex-math id="inft248">\begin{document}$E_{1}$\end{document}</tex-math></alternatives></inline-formula> will hover around this value. Once <inline-formula><alternatives><mml:math id="inf249"><mml:msub><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:math><tex-math id="inft249">\begin{document}$C_{1}$\end{document}</tex-math></alternatives></inline-formula> grows to <inline-formula><alternatives><mml:math id="inf250"><mml:mrow><mml:mi>D</mml:mi><mml:mi>/</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft250">\begin{document}$D / (\alpha_{1}- \gamma_{1})$\end{document}</tex-math></alternatives></inline-formula>, however, the active recruitment rate will equal the death rate. We can thus qualitatively describe the early dynamics of a cancer clone as follows: the mutation arises; the effector population grows to <inline-formula><alternatives><mml:math id="inf251"><mml:mrow><mml:mi>B</mml:mi><mml:mi>/</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:math><tex-math id="inft251">\begin{document}$B / D$\end{document}</tex-math></alternatives></inline-formula>; the clone grows to <inline-formula><alternatives><mml:math id="inf252"><mml:mrow><mml:mi>D</mml:mi><mml:mi>/</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft252">\begin{document}$D / (\alpha_{1}- \gamma_{1})$\end{document}</tex-math></alternatives></inline-formula>, at which point the effector population increases to properly (i.e. via active recruitment) combat the threat.</p><p>For most parameter choices in the main text, <inline-formula><alternatives><mml:math id="inf253"><mml:mrow><mml:mi>B</mml:mi><mml:mi>/</mml:mi><mml:mi>D</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft253">\begin{document}$B / D = O(1)$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf254"><mml:mrow><mml:mi>D</mml:mi><mml:mi>/</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo form="postfix" stretchy="false">)</mml:mo><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mi>O</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mn>2</mml:mn></mml:msup><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft254">\begin{document}$D / (\alpha_{1}- \gamma_{1}) = O(10^{2})$\end{document}</tex-math></alternatives></inline-formula>, so that the effector population size only manages to grow to more than a few cells once its targets number around a hundred. It is also worth mentioning that early ordinary differential equation models of tumour–immune dynamics phrased in a predator–prey fashion use Kuznetsov et al.’s estimate of effector passive recruitment being <inline-formula><alternatives><mml:math id="inf255"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>O</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft255">\begin{document}$O(10^{4})$\end{document}</tex-math></alternatives></inline-formula> cells per day (<xref ref-type="bibr" rid="bib38">Kuznetsov et al., 1994</xref>). With <inline-formula><alternatives><mml:math id="inf256"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>O</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0.1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft256">\begin{document}$O(0.1)$\end{document}</tex-math></alternatives></inline-formula> or <inline-formula><alternatives><mml:math id="inf257"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>O</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft257">\begin{document}$O(1)$\end{document}</tex-math></alternatives></inline-formula> new antigenic mutations (and thus effector types) generated in each division, when our cancer cell population size is <inline-formula><alternatives><mml:math id="inf258"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:mi>O</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft258">\begin{document}$O(10^{4})$\end{document}</tex-math></alternatives></inline-formula>, we therefore expect a passive recruitment similar to <xref ref-type="bibr" rid="bib38">Kuznetsov et al., 1994</xref>.</p><p>Models of immune responses vary in their triggers: Chen et al. suppose a minimal proportion of antigenic cancer cells (<xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>), the growth threshold conjecture requires a minimal cancer growth rate (<xref ref-type="bibr" rid="bib4">Arias et al., 2015</xref>), and most ordinary differential equation models as well as Lakatos et al. suppose instantaneous responses (<xref ref-type="bibr" rid="bib40">Lakatos et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">d’Onofrio, 2005</xref>). While our mechanistic model does not assume frequency dependence, the previous discussion implies that the immune response implicitly requires a certain cancer density before it can grow effectively to fight.</p></sec><sec sec-type="appendix" id="s8-4"><title>Effector cell population spikes</title><p>As identified in individual-based simulations (see <xref ref-type="fig" rid="fig2">Figure 2</xref>, for instance), effector subpopulations in the stochastic model can undergo rapid spiking events, before vanishing to zero when the targeted mutant (labelled by <inline-formula><alternatives><mml:math id="inf259"><mml:mi>i</mml:mi></mml:math><tex-math id="inft259">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>) goes extinct (and thus the effector cells have no more prey and so are removed from the system). These spikes arise when the mutation has immunogenicity <inline-formula><alternatives><mml:math id="inf260"><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft260">\begin{document}$I_{i}$\end{document}</tex-math></alternatives></inline-formula> much higher than the mean <inline-formula><alternatives><mml:math id="inf261"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>I</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft261">\begin{document}$\langle I \rangle$\end{document}</tex-math></alternatives></inline-formula>, as well as an antigenicity <inline-formula><alternatives><mml:math id="inf262"><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math><tex-math id="inft262">\begin{document}$A_{i}$\end{document}</tex-math></alternatives></inline-formula> lower than the mean <inline-formula><alternatives><mml:math id="inf263"><mml:mrow><mml:mo form="prefix" stretchy="false">⟨</mml:mo><mml:mi>A</mml:mi><mml:mo form="postfix" stretchy="false">⟩</mml:mo></mml:mrow></mml:math><tex-math id="inft263">\begin{document}$\langle A \rangle$\end{document}</tex-math></alternatives></inline-formula>, as otherwise the spike would not need to grow since the effector cells would be more efficient at killing. Qualitatively, we will write <inline-formula><alternatives><mml:math id="inf264"><mml:mover><mml:mi>I</mml:mi><mml:mo stretchy="false" class="tml-capshift" style="math-style:normal;math-depth:0;">^</mml:mo></mml:mover></mml:math><tex-math id="inft264">\begin{document}$\hat{I}$\end{document}</tex-math></alternatives></inline-formula> (<inline-formula><alternatives><mml:math id="inf265"><mml:mover><mml:mi>A</mml:mi><mml:mo stretchy="false" class="tml-capshift" style="math-style:normal;math-depth:0;">^</mml:mo></mml:mover></mml:math><tex-math id="inft265">\begin{document}$\hat{A}$\end{document}</tex-math></alternatives></inline-formula>) for the threshold immunogenicity (antigenicity) and above (below) which spikes may occur.</p><p>Effector spikes arise when the population sizes enter an orbit that ends when <inline-formula><alternatives><mml:math id="inf266"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo form="postfix" stretchy="false">)</mml:mo><mml:mo>&lt;</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft266">\begin{document}$C_{i}(t) \lt 1$\end{document}</tex-math></alternatives></inline-formula> (that is, extinction of mutation <inline-formula><alternatives><mml:math id="inf267"><mml:mi>i</mml:mi></mml:math><tex-math id="inft267">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>). We write <inline-formula><alternatives><mml:math id="inf268"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft268">\begin{document}$i = 1$\end{document}</tex-math></alternatives></inline-formula> for the mutation causes the spike, since we consider it to be arising in a neutral cell. (We argue qualitatively that were other antigenic mutations carried by the cell to generate an effector spike, they already would have; thus we expect most spikes to arise in neutral or almost neutral cells.)</p><p>Using that immunogenicities and antigenicities are drawn from exponential distributions with means 1, the rate of spikes <inline-formula><alternatives><mml:math id="inf269"><mml:msub><mml:mi>r</mml:mi><mml:mtext>spike</mml:mtext></mml:msub></mml:math><tex-math id="inft269">\begin{document}$r_{\text{spike}}$\end{document}</tex-math></alternatives></inline-formula> is then<disp-formula id="equ8"><label>(8)</label><alternatives><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>r</mml:mi><mml:mrow><mml:mtext>spike</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:mi>λ</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mover><mml:mi>I</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mover><mml:mi>A</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t8">\begin{document}$$\displaystyle r_{\text{spike}}= p_{a}\lambda\mathrm{e}^{-(\hat{I} + \hat{A})},$$\end{document}</tex-math></alternatives></disp-formula></p><p>since the rate of new antigenic mutations and the probabilities <inline-formula><alternatives><mml:math id="inf270"><mml:mrow><mml:mi>ℙ</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mover><mml:mi>I</mml:mi><mml:mo stretchy="false" class="tml-capshift" style="math-style:normal;math-depth:0;">^</mml:mo></mml:mover><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft270">\begin{document}$\mathbb{P}(I_{i}\gt \hat{I})$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf271"><mml:mrow><mml:mi>ℙ</mml:mi><mml:mo form="prefix" stretchy="false">(</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mover><mml:mi>A</mml:mi><mml:mo stretchy="false" class="tml-capshift" style="math-style:normal;math-depth:0;">^</mml:mo></mml:mover><mml:mo form="postfix" stretchy="false">)</mml:mo></mml:mrow></mml:math><tex-math id="inft271">\begin{document}$\mathbb{P}(A_{i}\gt \hat{A})$\end{document}</tex-math></alternatives></inline-formula> are independent.</p></sec><sec sec-type="appendix" id="s8-5"><title>Faster immune response</title><p>Our immune system possesses an innate pool of effector cells, able to respond to threats without the time-consuming training assumed implicitly in our specialised model of active and passive recruitment (<xref ref-type="bibr" rid="bib11">Chen and Mellman, 2013</xref>). With some probability, this pool might include effector cells that can recognise newly arising neoantigens quickly. Thus, rather than having to wait for the first passively recruited effector cell, the body could react faster to novel antigenic mutations.</p><p>To investigate the impact of this mechanism on the observed coevolution, we modified our model to include an effector cell of type <inline-formula><alternatives><mml:math id="inf272"><mml:mi>i</mml:mi></mml:math><tex-math id="inft272">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> upon initiation of antigenic mutation <inline-formula><alternatives><mml:math id="inf273"><mml:mi>i</mml:mi></mml:math><tex-math id="inft273">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula>. <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1A, B</xref> shows the average number of antigenic mutations per cell and <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1C, D</xref> shows the SFS, in the case of <inline-formula><alternatives><mml:math id="inf274"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft274">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>.</p><p>When comparing with the corresponding figures for the model used throughout the main text (<xref ref-type="fig" rid="fig4">Figure 4A, B</xref>, <xref ref-type="fig" rid="fig5">Figure 5B</xref>, and <xref ref-type="fig" rid="fig5">Figure 5F</xref>, respectively), the patterns appear the same, though more evident. This reinforces that the speed of the immune response increases its effectiveness, though it does not change the qualitative nature of cancer–immune coevolution. However, rather than having a guaranteed effector cell that can handle a newly arising neoantigen, there is some probability of the effector pool containing the desired specialty. Thus, we expect that in the body, selection will follow the patterns shown in both cases (<xref ref-type="fig" rid="fig4">Figures 4 and 5</xref> vs. <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>), at some magnitude between the two, related to the aforementioned probability.</p></sec></sec><sec sec-type="appendix" id="s9"><title>Extended figures</title><sec sec-type="appendix" id="s9-1"><title>Composition of effector population</title><p><xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref> illustrates the temporal dynamics of the composition of the effector cell population for the same two stochastic realisations shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. In the case of low mutation rate (<inline-formula><alternatives><mml:math id="inf275"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft275">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>, <xref ref-type="fig" rid="fig2">Figure 2A</xref>), the emergence of effector cells is delayed, and a single effector cell type dominates the population and then goes extinct after eliminating all antigenic targets. New types of effector cells arise again later when new antigenic mutations arise in cancer cells. In contrast, under high mutation rates (<inline-formula><alternatives><mml:math id="inf276"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft276">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, <xref ref-type="fig" rid="fig2">Figure 2B</xref>), the effector cells arise quickly in the start of the simulation and often multiple effector cell types dominate the population simultaneously.</p><p>When considered alongside <xref ref-type="fig" rid="fig2">Figure 2</xref>, these Muller plots demonstrate that spikes in the dynamics of the average antigenicity and immunogenicity are consistently associated with the expansion of specific dominating effector cell types in response to the presence of their specific antigenic targets.</p></sec><sec sec-type="appendix" id="s9-2"><title>Cyclic dynamics</title><p><xref ref-type="fig" rid="app1fig4">Appendix 1—figure 4</xref> shows the phase trajectories of cancer and effector cell abundances for the same two realisations presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>. Unlike classical predator–prey models, which often exhibit periodic dynamics, the phase trajectories of this system display more stochastic and irregular behaviour.</p><p>To quantify the cyclic dynamics of our simulations, we developed a method to enumerate the number of cycles present in each realisation. We track the directional changes in the phase portrait and accumulate the angular displacement. When the cumulative direction change exceeds 2π radians (anti-clockwise) or −2<italic>π</italic> radians (clockwise), we record this as one complete cycle. To validate the robustness of this approach, we applied the same methodology to a non-evolving predator–prey model with stochastic simulations, where the dynamics are relatively periodic. In short, the available reactions in the stochastic system are as follows:<disp-formula id="equ9"><label>(9)</label><alternatives><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mtext>prey birth</mml:mtext></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mtext>prey death</mml:mtext></mml:mpadded></mml:mover><mml:mi>∅</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mtext>predator death</mml:mtext></mml:mpadded></mml:mover><mml:mi>∅</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mtext>predation</mml:mtext></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mtd><mml:mtd><mml:mover><mml:mo>→</mml:mo><mml:mpadded width="+0.611em" lspace="0.278em" voffset=".15em"><mml:mtext>predator reproduction</mml:mtext></mml:mpadded></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mtext>prey</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>predator</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="t9">\begin{document}$$\displaystyle \begin{array}{ll}(\text{prey}) &amp;\xrightarrow{\text{prey birth}} (\text{prey}), (\text{prey})\\ (\text{prey}) &amp;\xrightarrow{\text{prey death}} \varnothing\\ (\text{predator}) &amp;\xrightarrow{\text{predator death}} \varnothing\\ (\text{prey}), (\text{predator}) &amp;\xrightarrow{\text{predation}} (\text{predator})\\ (\text{prey}), (\text{predator}) &amp;\xrightarrow{\text{predator reproduction}} (\text{prey}), (\text{predator}), (\text{predator}),\end{array}$$\end{document}</tex-math></alternatives></disp-formula></p><p>with the classical Lotka–Volterra predator–prey equation arising in the deterministic limit. With this, we observed mostly the same number of cycles across realisation (see <xref ref-type="fig" rid="app1fig5">Appendix 1—figure 5</xref>).</p><p>Applying this method, we obtain the distribution of cycle counts in our system shown in <xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>. For the low mutation rate case (<inline-formula><alternatives><mml:math id="inf277"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft277">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>), the majority of realisations exhibit no cycles, whereas for the hyper-mutated case (<inline-formula><alternatives><mml:math id="inf278"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft278">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), the number of cycles typically ranges from 1 to 2, with only a few realisations displaying more than 2 cycles within our simulation time. These cyclic dynamics are driven by the expansion of specific antigenic mutations that possess favourable characteristics: relatively high immunogenicity enabling substantial effector cell recruitment, coupled with relatively low antigenicity that prevents rapid elimination by the immune response (see <xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="app1fig3">Appendix 1—figure 3</xref>, as well as Appendix Section Effector cell population spikes). We further investigated the occurrence of irregular (clockwise) cycles, which are atypical in antagonistic interactions but possible under coevolution. As shown in <xref ref-type="fig" rid="app1fig7">Appendix 1—figure 7</xref>, approximately 10% of realisations in the high mutation rate case exhibit one or two irregular cycles. This suggests that while the system can exhibit irregular cyclic behaviour under certain conditions, such dynamics do not represent the predominant mode of behaviour.</p></sec><sec sec-type="appendix" id="s9-3"><title>Population dynamics</title><p><xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref> shows representative population dynamics (first row), along with the corresponding composition of the tumour population (second row), when <inline-formula><alternatives><mml:math id="inf279"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft279">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8A–D</xref>) and <inline-formula><alternatives><mml:math id="inf280"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft280">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8E–J</xref>). In the upper row, a blue histogram depicts the end times for the realisations, along with the average time <inline-formula><alternatives><mml:math id="inf281"><mml:msub><mml:mi>T</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:math><tex-math id="inft281">\begin{document}$T_{K}$\end{document}</tex-math></alternatives></inline-formula> to reach population size <inline-formula><alternatives><mml:math id="inf282"><mml:mrow><mml:mi>K</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mo>×</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><tex-math id="inft282">\begin{document}$K = 3 \times 10^{4}$\end{document}</tex-math></alternatives></inline-formula>, when applicable. (As seen in <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8I</xref>, all realisations go extinct, so no such <inline-formula><alternatives><mml:math id="inf283"><mml:msub><mml:mi>T</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:math><tex-math id="inft283">\begin{document}$T_{K}$\end{document}</tex-math></alternatives></inline-formula> is defined.) The red lines in the second row refer to the number of allowed antigenic mutations possessed by a cancer cell to consider it neutral. That is, the line labelled by three means that cells with three antigenic mutations are deemed neutral, whereas those with four antigenic mutations are considered antigenic and thus contribute to the proportion of the tumour that is antigenic. Note that since the immunogenicities and antigenicities are drawn from exponential distributions with mode 0, it is likely that many purportedly antigenic mutations <inline-formula><alternatives><mml:math id="inf284"><mml:mi>i</mml:mi></mml:math><tex-math id="inft284">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> have very weak immunogenicity <inline-formula><alternatives><mml:math id="inf285"><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≈</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:math><tex-math id="inft285">\begin{document}$I_{i}\approx 0$\end{document}</tex-math></alternatives></inline-formula> and antigenicity <inline-formula><alternatives><mml:math id="inf286"><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≈</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:math><tex-math id="inft286">\begin{document}$A_{i}\approx 0$\end{document}</tex-math></alternatives></inline-formula>. In this case, they would interact very rarely with the immune system (being effectively neutral), while still contributing to a count of cancer cells carrying antigenic mutations.</p><p>In <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8</xref>, the stopping time for the realisations <inline-formula><alternatives><mml:math id="inf287"><mml:msub><mml:mi>T</mml:mi><mml:mtext>end</mml:mtext></mml:msub></mml:math><tex-math id="inft287">\begin{document}$T_{\text{end}}$\end{document}</tex-math></alternatives></inline-formula> was made large so as to establish a good estimate on the average time <inline-formula><alternatives><mml:math id="inf288"><mml:msub><mml:mi>T</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:math><tex-math id="inft288">\begin{document}$T_{K}$\end{document}</tex-math></alternatives></inline-formula> that the cancer cell population (in the non-suppressed case) reaches the stopping population size <inline-formula><alternatives><mml:math id="inf289"><mml:mi>K</mml:mi></mml:math><tex-math id="inft289">\begin{document}$K$\end{document}</tex-math></alternatives></inline-formula>. Due to the stochasticity of the model, there is a distribution over end times for each realisation even for a single set of parameters. It is clear from the difference in values of the mean <inline-formula><alternatives><mml:math id="inf290"><mml:msub><mml:mi>T</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:math><tex-math id="inft290">\begin{document}$T_{K}$\end{document}</tex-math></alternatives></inline-formula> for <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8A, C</xref> (likewise for <xref ref-type="fig" rid="app1fig8">Appendix 1—figure 8E, G</xref>) that the immune system plays a role in slowing the cancer growth, since <inline-formula><alternatives><mml:math id="inf291"><mml:mrow><mml:mtext>avg </mml:mtext><mml:msubsup><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:mtext mathvariant="bold">A</mml:mtext></mml:msubsup><mml:mo>&lt;</mml:mo></mml:mrow><mml:mrow><mml:mtext>avg </mml:mtext><mml:msubsup><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:mtext mathvariant="bold">C</mml:mtext></mml:msubsup></mml:mrow></mml:math><tex-math id="inft291">\begin{document}$\text{avg }T_{K}^{\text{\textbf{A}}}\lt \text{avg }T_{K}^{\text{\textbf{C}}}$\end{document}</tex-math></alternatives></inline-formula> (and <inline-formula><alternatives><mml:math id="inf292"><mml:mrow><mml:mtext>avg </mml:mtext><mml:msubsup><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:mtext mathvariant="bold">E</mml:mtext></mml:msubsup><mml:mo>&lt;</mml:mo></mml:mrow><mml:mrow><mml:mtext>avg </mml:mtext><mml:msubsup><mml:mi>T</mml:mi><mml:mi>K</mml:mi><mml:mtext mathvariant="bold">G</mml:mtext></mml:msubsup></mml:mrow></mml:math><tex-math id="inft292">\begin{document}$\text{avg }T_{K}^{\text{\textbf{E}}}\lt \text{avg }T_{K}^{\text{\textbf{G}}}$\end{document}</tex-math></alternatives></inline-formula>).</p></sec><sec sec-type="appendix" id="s9-4"><title>Heat maps</title><p><xref ref-type="fig" rid="app1fig9">Appendix 1—figure 9A, B</xref> depicts the extinction times for simulations run with <inline-formula><alternatives><mml:math id="inf293"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft293">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf294"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft294">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, respectively. <xref ref-type="fig" rid="app1fig10">Appendix 1—figure 10A–C and D–F</xref> depicts what proportion of tumour cells carry antigenic mutations for simulations run with <inline-formula><alternatives><mml:math id="inf295"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft295">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf296"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft296">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, respectively. The first row allows no antigenic mutations in neutral cancer cells; the second (third) row allows one (two) antigenic mutation(s) before a cell is considered antigenic.</p></sec><sec sec-type="appendix" id="s9-5"><title>Genetics</title><p>When the immune system is absent, the SFS and MBD are well approximated by the theoretical predictions (black dashed lines; see <xref ref-type="fig" rid="app1fig11">Appendix 1—figure 11</xref>). In the presence of an immune system, however, the MBDs deviate from their theoretical predictions, as expected. When hyper-mutated tumours are considered (<inline-formula><alternatives><mml:math id="inf297"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft297">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>), the genetic footprints of selection are more pronounced. <xref ref-type="fig" rid="app1fig12">Appendix 1—figure 12</xref> depicts the average number of antigenic mutations per cancer cell, and <xref ref-type="fig" rid="app1fig13">Appendix 1—figure 13</xref> shows the SFS and MBD in this regime.</p><p>To validate the sensitivity of the Wasserstein distance to interaction parameters, we plot a heat map (<xref ref-type="fig" rid="app1fig14">Appendix 1—figure 14</xref>), which shows the similarity pattern with <xref ref-type="fig" rid="fig3">Figure 3</xref> that with the increase of interaction parameters, the MBD deviates from the theoretical predictions as expected.</p><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Genetic evidence of selection for a faster-acting immune system.</title><p>(<bold>A, B</bold>) Average number of antigenic mutations per cell in solid orange lines for several representative realisations when <inline-formula><alternatives><mml:math id="inf298"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft298">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>. Theoretical prediction for the accumulation of neutral mutations per cell in an exponentially growing population shown in grey dashed line. (<bold>C, D</bold>) Simulated SFS for antigenic mutations averaged over 100 realisations when <inline-formula><alternatives><mml:math id="inf299"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft299">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (orange points), along with the theoretical predictions (black dashed lines) in the absence of an immune response. (<bold>A</bold>, <bold>C</bold>) Low immune effect: <inline-formula><alternatives><mml:math id="inf300"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.002</mml:mn></mml:mrow></mml:math><tex-math id="inft300">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf301"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft301">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>. (<bold>B, C</bold>) High immune effect: <inline-formula><alternatives><mml:math id="inf302"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft302">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf303"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft303">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>. (Parameter sets chosen as points <inline-formula><alternatives><mml:math id="inf304"><mml:mi>a</mml:mi></mml:math><tex-math id="inft304">\begin{document}$a$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf305"><mml:mi>b</mml:mi></mml:math><tex-math id="inft305">\begin{document}$b$\end{document}</tex-math></alternatives></inline-formula> from <xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig1-v1.tif"/></fig><fig id="app1fig2" position="float"><label>Appendix 1—figure 2.</label><caption><title>Neoantigen burden distribution (NBD) (yellow lines) and the corresponding distribution for immunogenicity (purple lines) averaged over 100 realisations, when <inline-formula><alternatives><mml:math id="inf306"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft306">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<bold>A, B</bold>) and <inline-formula><alternatives><mml:math id="inf307"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft307">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<bold>C, D</bold>), for both low (dotted lines) and high (solid lines) immune effectiveness.</title><p>All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig2-v1.tif"/></fig><fig id="app1fig3" position="float"><label>Appendix 1—figure 3.</label><caption><title>Muller plots for two representative realisations from <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>(<bold>A</bold>, <bold>B</bold>) correspond to <xref ref-type="fig" rid="fig2">Figure 2A, B and C, D</xref>, respectively. Vertical dashed grey lines in all panels refer to the timing of spikes in the effector population in <xref ref-type="fig" rid="fig2">Figure 2</xref>, also indicated by vertical dashed grey lines. The colour indicates the antigenicity and immunogenicity of the antigen corresponding to each effector type, as shown in the colour maps on the right. White regions indicate the absence of effector cells, while grey represents all rare effector types whose abundance remains below 5%. Interaction parameters: <inline-formula><alternatives><mml:math id="inf308"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft308">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf309"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft309">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula> (<bold>A</bold>); <inline-formula><alternatives><mml:math id="inf310"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft310">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf311"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft311">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula> (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig3-v1.tif"/></fig><fig id="app1fig4" position="float"><label>Appendix 1—figure 4.</label><caption><title>Phase trajectories of two realisations in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title><p>(<bold>A, B</bold>) are corresponding to <xref ref-type="fig" rid="fig2">Figure 2A, B and C, D</xref>, respectively. Interaction parameters: <inline-formula><alternatives><mml:math id="inf312"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft312">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf313"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft313">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula> (<bold>A</bold>); <inline-formula><alternatives><mml:math id="inf314"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft314">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf315"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft315">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula> (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig4-v1.tif"/></fig><fig id="app1fig5" position="float"><label>Appendix 1—figure 5.</label><caption><title>Validation of our cycle counting method in a non-evolving prey–predator system.</title><p>(<bold>A</bold>) Population dynamics of the deterministic system (dark lines) with 20 stochastic realisations (pale lines). (<bold>B</bold>) Inferred number of predator–prey cycles using the same methodology as in <xref ref-type="fig" rid="app1fig6">Appendix 1—figure 6</xref>. Model parameters, from <xref ref-type="disp-formula" rid="equ9">Equation 9</xref>: prey birth rate = 1, prey death rate = 0.1, predator death rate = 0.1, predation rate = 0.001, and predator reproduction rate = 0.0001. Initial population sizes of the prey and the predator were 1000 and 700, respectively, with a maximum simulation time of 100. The histogram is constructed from 500 independent realisations.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig5-v1.tif"/></fig><fig id="app1fig6" position="float"><label>Appendix 1—figure 6.</label><caption><title>Histograms depicting the inferred number of cycles in the population dynamics.</title><p>(<bold>A, B</bold>) Distribution of cycle counts for simulations with, respectively, low (<inline-formula><alternatives><mml:math id="inf316"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft316">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>) and high (<inline-formula><alternatives><mml:math id="inf317"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft317">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>) mutation rates. Each histogram is constructed from 200 independent realisations. The interaction parameters are <inline-formula><alternatives><mml:math id="inf318"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft318">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf319"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft319">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula> (<bold>A</bold>); <inline-formula><alternatives><mml:math id="inf320"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft320">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf321"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft321">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula> (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig6-v1.tif"/></fig><fig id="app1fig7" position="float"><label>Appendix 1—figure 7.</label><caption><title>Histograms depicting the inferred number of irregular (clockwise) cycles in the population dynamics.</title><p>(<bold>A, B</bold>) Distribution of cycle counts for simulations with, respectively, low (<inline-formula><alternatives><mml:math id="inf322"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft322">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>) and high (<inline-formula><alternatives><mml:math id="inf323"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft323">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>) mutation rates. Each histogram is constructed from 200 independent realisations. The interaction parameters are <inline-formula><alternatives><mml:math id="inf324"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft324">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf325"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft325">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula> (<bold>A</bold>); <inline-formula><alternatives><mml:math id="inf326"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft326">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf327"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft327">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula> (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig7-v1.tif"/></fig><fig id="app1fig8" position="float"><label>Appendix 1—figure 8.</label><caption><title>Cancer–effector population dynamics (first row) and tumour antigenicity (second row) for five different sets of parameters.</title><p>(<bold>A, B</bold>) <inline-formula><alternatives><mml:math id="inf328"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft328">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf329"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.002</mml:mn></mml:mrow></mml:math><tex-math id="inft329">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf330"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft330">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>. (<bold>C, D</bold>) <inline-formula><alternatives><mml:math id="inf331"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft331">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf332"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft332">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf333"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft333">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>. (<bold>E, F</bold>) <inline-formula><alternatives><mml:math id="inf334"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft334">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf335"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.002</mml:mn></mml:mrow></mml:math><tex-math id="inft335">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf336"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft336">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>. (<bold>G, H</bold>) <inline-formula><alternatives><mml:math id="inf337"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft337">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf338"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft338">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf339"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft339">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula>. (<bold>I, J</bold>) <inline-formula><alternatives><mml:math id="inf340"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft340">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, <inline-formula><alternatives><mml:math id="inf341"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft341">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf342"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft342">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>. In the first row, red lines depict cancer cell population sizes for several representative realisations. Blue histograms above show the final time <inline-formula><alternatives><mml:math id="inf343"><mml:msub><mml:mi>T</mml:mi><mml:mi>K</mml:mi></mml:msub></mml:math><tex-math id="inft343">\begin{document}$T_{K}$\end{document}</tex-math></alternatives></inline-formula> where the population size reached <inline-formula><alternatives><mml:math id="inf344"><mml:mrow><mml:mi>K</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>3</mml:mn><mml:mo>×</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mn>4</mml:mn></mml:msup></mml:mrow></mml:math><tex-math id="inft344">\begin{document}$K = 3 \times 10^{4}$\end{document}</tex-math></alternatives></inline-formula> for all non-extinct realisations, with a mean given by a dashed vertical black line. In the second row, red lines with increasing paleness, labelled by <inline-formula><alternatives><mml:math id="inf345"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:math><tex-math id="inft345">\begin{document}$i = 0$\end{document}</tex-math></alternatives></inline-formula>, 1, 3, or 5, depict the proportion of cancer cells contain <inline-formula><alternatives><mml:math id="inf346"><mml:mi>i</mml:mi></mml:math><tex-math id="inft346">\begin{document}$i$\end{document}</tex-math></alternatives></inline-formula> or more antigenic mutations. All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig8-v1.tif"/></fig><fig id="app1fig9" position="float"><label>Appendix 1—figure 9.</label><caption><title>Extinction time heat maps for <inline-formula><alternatives><mml:math id="inf347"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft347">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<bold>A</bold>) and <inline-formula><alternatives><mml:math id="inf348"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft348">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<bold>B</bold>). All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig9-v1.tif"/></fig><fig id="app1fig10" position="float"><label>Appendix 1—figure 10.</label><caption><title>Heat maps depicting the tumour composition (that is, the proportion of tumour cells that are antigenic) for <inline-formula><alternatives><mml:math id="inf349"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft349">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula> (<bold>A—C</bold>) and <inline-formula><alternatives><mml:math id="inf350"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft350">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula> (<bold>D—F</bold>).</title><p>The first row (A &amp; D) is where one antigenic mutation held by a cell makes the cell antigenic; the second (B &amp; E) and third rows (C &amp; F) allow for one and two antigenic mutations (respectively) to be possessed by a cancer cell while still considering it neutral. Points 𝑎 and 𝑐 (respectively, 𝑏 and 𝑑) label parameter sets of low (respectively, high) immune effectiveness. All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig10-v1.tif"/></fig><fig id="app1fig11" position="float"><label>Appendix 1—figure 11.</label><caption><title>Genetic markers of selection: SFS (<bold>A, B</bold>) and MBD (<bold>C, D</bold>) for no immune effect case (all interaction parameters set to 0) averaged over 100 realisations when <inline-formula><alternatives><mml:math id="inf351"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft351">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>, along with the theoretical predictions (black dashed lines) in the absence of an immune response.</title><p>Green data represents neutral mutations (<bold>A, C</bold>) and orange data represents antigenic mutations (<bold>B, D</bold>), with vertical lines representing the means of the distributions for MBDs in panels (<bold>C</bold>, <bold>D</bold>). All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig11-v1.tif"/></fig><fig id="app1fig12" position="float"><label>Appendix 1—figure 12.</label><caption><title>Average number of antigenic mutations in solid orange lines for several representative realisations when <inline-formula><alternatives><mml:math id="inf352"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft352">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>.</title><p>Theoretical prediction for the accumulation of neutral mutations in an exponentially growing population is shown in grey dashed line. (<bold>A</bold>) Low immune effect: <inline-formula><alternatives><mml:math id="inf353"><mml:mstyle><mml:mrow><mml:mstyle displaystyle="false"><mml:msub><mml:mi>α</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.002</mml:mn></mml:mstyle></mml:mrow></mml:mstyle></mml:math><tex-math id="inft353">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf354"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft354">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>. (<bold>B</bold>) Middling immune effect: <inline-formula><alternatives><mml:math id="inf355"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft355">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf356"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft356">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula>. (<bold>C</bold>) High immune effect: <inline-formula><alternatives><mml:math id="inf357"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.03</mml:mn></mml:mrow></mml:math><tex-math id="inft357">\begin{document}$\alpha_{0}= 0.03$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf358"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.3</mml:mn></mml:mrow></mml:math><tex-math id="inft358">\begin{document}$\beta_{0}= 0.3$\end{document}</tex-math></alternatives></inline-formula>. (Parameter sets for (<bold>A</bold>) and (<bold>C</bold>) chosen as points <inline-formula><alternatives><mml:math id="inf359"><mml:mi>c</mml:mi></mml:math><tex-math id="inft359">\begin{document}$c$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf360"><mml:mi>d</mml:mi></mml:math><tex-math id="inft360">\begin{document}$d$\end{document}</tex-math></alternatives></inline-formula> from <xref ref-type="fig" rid="fig3">Figure 3C</xref>, respectively.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig12-v1.tif"/></fig><fig id="app1fig13" position="float"><label>Appendix 1—figure 13.</label><caption><title>Genetic markers of selection: SFS (<bold>A, B</bold>, <bold>E, F</bold>) and MBD (<bold>C, D</bold>, <bold>G, H</bold>) for low (left column; <inline-formula><alternatives><mml:math id="inf361"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.002</mml:mn></mml:mrow></mml:math><tex-math id="inft361">\begin{document}$\alpha_{0}= 0.002$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf362"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.001</mml:mn></mml:mrow></mml:math><tex-math id="inft362">\begin{document}$\beta_{0}= 0.001$\end{document}</tex-math></alternatives></inline-formula>, point c in <xref ref-type="fig" rid="fig3">Figure 3</xref>) and high (right column; <inline-formula><alternatives><mml:math id="inf363"><mml:mrow><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.005</mml:mn></mml:mrow></mml:math><tex-math id="inft363">\begin{document}$\alpha_{0}= 0.005$\end{document}</tex-math></alternatives></inline-formula> and <inline-formula><alternatives><mml:math id="inf364"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>0.01</mml:mn></mml:mrow></mml:math><tex-math id="inft364">\begin{document}$\beta_{0}= 0.01$\end{document}</tex-math></alternatives></inline-formula>, point d in <xref ref-type="fig" rid="fig3">Figure 3</xref>) immune effectiveness averaged over 100 realisations when <inline-formula><alternatives><mml:math id="inf365"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math><tex-math id="inft365">\begin{document}$\lambda = 10$\end{document}</tex-math></alternatives></inline-formula>, along with the theoretical predictions (black dashed lines) in the absence of an immune response.</title><p>Green data represents neutral mutations (<bold>A</bold>, <bold>C</bold>, <bold>E, G</bold>) and orange data represents antigenic mutations (<bold>B</bold>, <bold>D</bold>, <bold>F, H</bold>), with vertical lines representing the means of the distributions for MBDs in panels (<bold>C</bold>, <bold>D</bold>, <bold>G, H</bold>). All parameter values not specified here are listed in <xref ref-type="table" rid="table1">Table 1</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig13-v1.tif"/></fig><fig id="app1fig14" position="float"><label>Appendix 1—figure 14.</label><caption><title>Heat maps illustrate the differences between the simulated and theoretical single-cell mutation burden distributions when <inline-formula><alternatives><mml:math id="inf366"><mml:mrow><mml:mi>λ</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:math><tex-math id="inft366">\begin{document}$\lambda = 1$\end{document}</tex-math></alternatives></inline-formula>.</title><p>The colour gradient represents the Wasserstein distance, with the number of mutations <inline-formula><alternatives><mml:math id="inf367"><mml:mi>k</mml:mi></mml:math><tex-math id="inft367">\begin{document}$k$\end{document}</tex-math></alternatives></inline-formula> rescaled to the interval [0,1]. The left panel displays how the difference between simulated and theoretical predicted neutral MBDs varies with interaction parameters, while the right panel shows the same for antigenic mutations. Point a and b are the same in <xref ref-type="fig" rid="fig3">Figure 3</xref> and all other parameter values can be found in <xref ref-type="table" rid="table1">Table 1</xref> in the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-103970-app1-fig14-v1.tif"/></fig></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103970.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shou</surname><given-names>Wenying</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University College London</institution><country>United Kingdom</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> work presents a stochastic branching process model of tumour-immune coevolution, incorporating stochastic antigenic mutation accumulation and escape within the cancer cell population. They then used this model to investigate how tumour-immune interactions influence tumour outcome and the summary statistics of sequencing data of bulk and single-cell sequencing of a tumour. The evidence is <bold>compelling</bold> and the work will be of interest to cancer-immune biology fields.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103970.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The topic of tumor-immune co-evolution is an important, understudied topic with, as the authors noted, a general dearth of good models in this space. The authors have made important progress on the topic by introduced a stochastic branching process model of antigenicity / immunogenicity and measuring the proportion of simulated tumors which go extinct. The model is extensively explored and authors provide some nice theoretical results in addition to simulated results, including an analysis of increasing cancer/immune versus cyclical cancer/immune dynamics. The analysis appropriately builds upon the foundation of other work in the field of predicting site frequency spectrum, but extends the results into cancer-immune co-evolution in an intuitive computational framework.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.103970.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Long</given-names></name><role specific-use="author">Author</role><aff><institution>Sun Yat-sen University</institution><addr-line><named-content content-type="city">Guangzhou</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Morison</surname><given-names>Christo</given-names></name><role specific-use="author">Author</role><aff><institution>Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Weini</given-names></name><role specific-use="author">Author</role><aff><institution>Queen Mary University of London</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public review):</bold></p><p>Summary:</p><p>The topic of tumor-immune co-evolution is an important, understudied topic with, as the authors noted, a general dearth of good models in this space. The authors have made important progress on the topic by introducing a stochastic branching process model of antigenicity/immunogenicity and measuring the proportion of simulated tumors that go extinct. The model is extensively explored, and the authors provide some nice theoretical results in addition to simulated results.</p></disp-quote><p>We thank the reviewer for the positive comments on our work.</p><disp-quote content-type="editor-comment"><p>Major comments</p><p>The text in lines 183-191 is intuitively and nicely explained. However, I am not sure all of it follows from the figure panels in Figure 2. For example, the authors refer to a mutation that has a large immunogenicity, but it's not shown how many mutations, or the relative size of the mutations in Figure 2. The same comment holds true for the claim that spikes also arise for mutations with low antigenicity.</p></disp-quote><p>We thank the reviewer for helping us to further specify this statement in our original submission. We now added muller plots in a new Appendix Figure (Figure A3) presenting the relative abundances of different types of effector cells in the population over time. Each effector type is colour-coded with its antigenicity and immunogenicity. To align with this Appendix Figure (Figure A3), we also updated our Figure 2 generated under the same realisation as Figure A3. We can now see clearly that the spikes in the mean values of the antigenicity and immunogenicity over the whole effector populations in new Figure 2B&amp;2D indeed correspond to the expansion of single or several antigenic mutations recruiting the specific effector cell types. For example, in Figure 2B, we can see that the spikes of low average antigenicity and high immunogenicity (around time 11) happen at the same time when an effector type in Figure A3 with such a trait (coloured in green) arises and takes over the population. We have rewritten our Results section related (Line 192 - Line 222 in main text and Appendix A6).</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public review):</bold></p><p>Summary:</p><p>In this work, the authors developed a model of tumour-immune dynamics, incorporating stochastic antigenic mutation accumulation and escape within the cancer cell population. They then used this model to investigate how tumour-immune interactions influence tumour outcome and summary statistics of sequencing data.</p><p>Strengths:</p><p>This novel modeling framework addresses an important and timely topic. The authors consider the useful question of how bulk and single-cell sequencing may provide insights into the tumourimmune interactions and selection processes.</p></disp-quote><p>We thank the reviewer for the positive comments.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>One set of conclusions presented in the paper is the presence of cyclic dynamics between effector/cancer cells, antigenicity, and immunogenicity. However, these conclusions are supported in the manuscript by two sample trajectories of stochastic simulations, and these provide mixed support for the conclusions (i.e. the phasing asynchrony described in the text does not seem to apply to Figure 2C).</p></disp-quote><p>We have now developed a method to quantify the cyclic dynamics in our system (Appendix A7), where can track the directional changes phase portrait of the abundances of the cancer and effector cells. We first tested this method in a non-evolving stochastic predator-prey system, where our method can correctly capture the number of cycles in this system (Figure A7). We then use this method to quantify the number of cycles we observed between cancer and effector cells under different mutation rates (Figure A5) as well as whether they are counter-clockwise or clockwise cycles (Figure A6). Our results showed that the cyclic dynamics are more often to be observed when mutation rates are higher, and the majority of those cycles are counter-clockwise. When the mutation rate is high, we observe an increase of clockwise cycles, which have been observed in predator-prey systems and explained through coevolution. However, even under high mutation rates, counter-clockwise cycles are still the more frequent type.</p><p>In our simulations, we observed rarely out-of-phase cycles, which was by chance present in our original Figure 2. We have now removed that statement about out-of-phase cycles and replaced by more systematic analysis of the cyclic dynamics as described above (Line 192 to 207 in the revised version). We thank the constructive comment of the reviewer, which motivated us to improve our analysis significantly.</p><disp-quote content-type="editor-comment"><p>Similarly, the authors also find immune selection effects on the shape of the mutational burden in Figure 5 D/H using a qualitative comparison between the distributions and theoretical predictions in the absence of immune response. However the discrepancy appears quite small in panel D, and there are no quantitative comparisons provided to evaluate the significance. An analysis of the robustness of all the conclusions to parameter variation is missing.</p></disp-quote><p>We have now added statistical analysis using Wasserstein distance between the simulated mutation burden distribution and theoretical (neutral) expectation in Figure 5 C, D, G, H as well as in Figure A11 C&amp;D when there is no cancer-immune interaction. We can see that the measurements of the Wasserstein distance agrees with our statement, that the higher immune effectiveness leads to larger deviation from the neutral expectation.</p><disp-quote content-type="editor-comment"><p>Lastly, the role of the Appendix results in the main messages of the paper is unclear.</p></disp-quote><p>We agree with the review and have now removed the Appendix sections “Deterministic Analysis”.</p><disp-quote content-type="editor-comment"><p>Reviewing Editor Comments:</p><p>I find the abstract too long. For example, &quot;Knowledge of this coevolutionary system and the selection taking place within it can help us understand tumour-immune dynamics both during tumorigenesis but also when treatments such as immunotherapies are applied.&quot; can be shortened to: &quot;Knowledge of this coevolutionary system can help us understand tumour-immune dynamics both during tumorigenesis and during immunotherapy treatments.&quot;</p></disp-quote><p>We agree and have taken the suggestion of the reviewer to shorten our abstract.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>The discussion at lines 134-140, centered around Figure A1, is an important and nicely constructed feature of the model.</p><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>I suggest that the authors conduct a more in-depth analysis of their conclusions on cyclic dynamics over a large set of sample paths.</p></disp-quote><p>Done and please see our detailed response to the reviewer 2 above.</p><disp-quote content-type="editor-comment"><p>In addition, statistical comparisons between the observed mutational burden distribution and theoretical predictions in the absence of immune selection should be carried out to support their conclusions. In all cases, conclusions should be tested extensively for robustness/sensitivity to parameters.</p></disp-quote><p>Done and please see our detailed response to the reviewer 2 above.</p><disp-quote content-type="editor-comment"><p>Here are some specific suggestions/comments:</p><p>(1) Please provide a precise mathematical description of the model to complement Figure 1.</p></disp-quote><p>We have significantly revised our “Model” section to provide a precise mathematical description of our model (Line 138 - 148). Please also see our document showing the difference between the revised version and original submission.</p><disp-quote content-type="editor-comment"><p>(2) Section on &quot;Interactions dictate outcome of tumour progress&quot; and Figure 3: please define 'tumour outcome' - are the heatmaps produced in Figure 3 tumor size reflecting whether or not the population has reached level K before a particular time? Also, I do not see a definition for the 'slowgrowing' tumour proportion plotted in Figure 3CF or in the accompanying text.</p></disp-quote><p>We have now added the definition of “tumour outcome” in our “Model” section (line 171 to 176), where we explain our model parameters and quantities measured in the following “Results” section.</p><disp-quote content-type="editor-comment"><p>(3) Figure 5C/G: the green dotted vertical line is difficult to see.</p></disp-quote><p>We have now changed the mean of the simulations to solid red lines instead of using the green dotted vertical lines previously.</p><disp-quote content-type="editor-comment"><p>(4) Appendix A1 text under (A2) should U/N be U/C? N does not appear to be defined.</p></disp-quote><p>We have more removed the previous A1 section. Please see our response to reviewer 2 as well.</p><disp-quote content-type="editor-comment"><p>(5) Text under (A5): it is unclear what is meant by &quot;SFS must be heavy tailed (that is, more heterogeneous)&quot; -- a more precise statement regarding tail decay rate and associated consequences would be more helpful.</p></disp-quote><p>We have more removed the previous A section, where the original text &quot;...SFS must be heavy-tailed&quot; was.</p><disp-quote content-type="editor-comment"><p>(6) Section A4 and Figure A1: can these calculations be compared to simulations?</p></disp-quote><p>We have more removed the previous A section on the deterministic analysis as they are not so relevant to our stochastic simulations indeed. Please see our response to reviewer 2 as well.</p><disp-quote content-type="editor-comment"><p>(7) Also, in general, please clarify how the results in the Appendix are used in the main text conclusions or provide insights relevant to these conclusions. If they are not, one can consider removing them.</p></disp-quote><p>We have more removed the previous A section on the deterministic analysis. The remaining sections are about stochastic simulations and extended figures which support our main figures.</p><disp-quote content-type="editor-comment"><p>(8) Figure A2: the two lines are difficult to tell apart on each panel. Please consider different styles.</p></disp-quote><p>We have changed one of the dotted lines to be solid. This figure is now Figure A1 in our revision.</p></body></sub-article></article>